Robert A Hegele

List of Publications by Year in Descending Order

714 papers	38,446 citations	90 h-index	170 g-index
809 ext. papers	45,334 ext. citations	6.8 avg, IF	7.51 L-index

#	Paper	IF	Citations
714	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study.. *Lancet, The*, **2022**,	40	4
713	Web of Science's Citation Median Metrics Overcome the Major Constraints of the Journal Impact Factor.. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2022**, ATVBAHA122317426	9.4	
712	Is Deprescription of Ezetimibe Safe in Familial Hypercholesterolemia Patients Taking Evolocumab?. *CJC Open*, **2022**, 4, 428-431	2	
711	Treatment of Homozygous Familial Hypercholesterolemia With Evinacumab.. *CJC Open*, **2022**, 4, 347-349	2	0
710	Effectiveness of a Novel ⊟ Krill Oil Agent in Patients With Severe Hypertriglyceridemia: A Randomized Clinical Trial.. *JAMA Network Open*, **2022**, 5, e2141898	10.4	2
709	Disorders of Lipoprotein Metabolism **2022**, 1035-1055		
708	A Case Series Assessing the Effects of Lomitapide on Carotid Intima-Media Thickness in Adult Patients with Homozygous Familial Hypercholesterolaemia in a Real-World Setting.. *Advances in Therapy*, **2022**, 39, 1857	4.1	1
707	Monogenic Versus Polygenic Forms of Hypercholesterolemia and Cardiovascular Risk: Are There Any Differences?. *Current Atherosclerosis Reports*, **2022**, 1	6	1
706	Sortilin enhances secretion of apolipoprotein(a) through effects on apolipoprotein B secretion and promotes uptake of lipoprotein(a).. *Journal of Lipid Research*, **2022**, 100216	6.3	0
705	Hypertriglyceridemia in young adults with a 22q11.2 microdeletion.. *European Journal of Endocrinology*, **2022**, 187, 91-99	6.5	0
704	Lipid-Modifying Therapies and Stroke Prevention.. *Current Neurology and Neuroscience Reports*, **2022**, 1	6.6	
703	Effective, disease-modifying, clinical approaches to patients with mild-to-moderate hypertriglyceridaemia.. *Lancet Diabetes and Endocrinology,the*, **2021**,	18.1	1
702	The Clinical Genome Resource (ClinGen) Familial Hypercholesterolemia Variant Curation Expert Panel consensus guidelines for LDLR variant classification.. *Genetics in Medicine*, **2021**,	8.1	6
701	Influence of the LDL-receptor genotype on statin response in heterozygous familial hypercholesterolemia: insights from the Canadian FH Registry. *Canadian Journal of Cardiology*, **2021**,	3.8	1
700	Familial combined hyperlipidemia is a polygenic trait. *Current Opinion in Lipidology*, **2021**,	4.4	2
699	A modern approach to dyslipidemia. *Endocrine Reviews*, **2021**,	27.2	10
698	Integrated Analysis of the Pancreas and Islets Reveals Unexpected Findings in Human Male With Type 1 Diabetes. *Journal of the Endocrine Society*, **2021**, 5, bvab162	0.4	

697	Apolipoprotein genetic variants and hereditary amyloidosis. *Current Opinion in Lipidology*, **2021**, 32, 132-140	4.4	2
696	Evidence of synergism among three genetic variants in a patient with LMNA-related lipodystrophy and amyotrophic lateral sclerosis leading to a remarkable nuclear phenotype. *Molecular and Cellular Biochemistry*, **2021**, 476, 2633-2650	4.2	2
695	Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD. *Journal of Clinical Lipidology*, **2021**, 15, 275-291	4.9	4
694	Enrichment of loss-of-function and copy number variants in ventricular cardiomyopathy genes in 'lone' atrial fibrillation. *Europace*, **2021**, 23, 844-850	3.9	2
693	Improving reporting standards for polygenic scores in risk prediction studies. *Nature*, **2021**, 591, 211-219	50.4	70
692	Novel PPARG mutation in multiple family members with chylomicronemia. *Journal of Clinical Lipidology*, **2021**, 15, 431-434	4.9	1
691	Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Diabetes and Endocrinology,the*, **2021**, 9, 264-275	18.1	28
690	Evaluating Polygenic Risk Scores in "Lone" Atrial Fibrillation. *CJC Open*, **2021**, 3, 751-757	2	1
689	Lipid effects of glucagon-like peptide 1 receptor analogs. *Current Opinion in Lipidology*, **2021**, 32, 191-199	4.4	3
688	Saudi Familial Hypercholesterolemia Patients With Rare Stop Gain Variant Showed Variable Clinical Phenotype and Resistance to Multiple Drug Regimen. *Frontiers in Medicine*, **2021**, 8, 694668	4.9	2
687	Prevalence of severe hypertriglyceridemia and pancreatitis in familial partial lipodystrophy type 2. *Journal of Clinical Lipidology*, **2021**,	4.9	3
686	Simplifying Detection of Copy-Number Variations in Maturity-Onset Diabetes of the Young. *Canadian Journal of Diabetes*, **2021**, 45, 71-77	2.1	
685	Liver Injury Associated With Ezetimibe Monotherapy. *CJC Open*, **2021**, 3, 195-197	2	2
684	Combined hyperlipidemia is genetically similar to isolated hypertriglyceridemia. *Journal of Clinical Lipidology*, **2021**, 15, 79-87	4.9	9
683	Ancestry-specific profiles of genetic determinants of severe hypertriglyceridemia. *Journal of Clinical Lipidology*, **2021**, 15, 88-96	4.9	2
682	Ketogenic diets, not for everyone. *Journal of Clinical Lipidology*, **2021**, 15, 61-67	4.9	11
681	Editorial comment: when Mendelian randomization goes astray. *Current Opinion in Lipidology*, **2021**, 32, 79-80	4.4	0
680	Abetalipoproteinemia Due to a Novel Splicing Variant in in 3 Siblings. *Journal of Investigative Medicine High Impact Case Reports*, **2021**, 9, 23247096211022484	1.2	0

679	Lipoprotein and Lipid Metabolism **2021**, 235-278		0
678	Clinical and Mutation Spectra of Cockayne Syndrome in India. *Neurology India*, **2021**, 69, 362-366	0.7	2
677	Human variant of scavenger receptor BI (R174C) exhibits impaired cholesterol transport functions. *Journal of Lipid Research*, **2021**, 62, 100045	6.3	4
676	Role of Common Genetic Variation in Lone Atrial Fibrillation. *Circulation Genomic and Precision Medicine*, **2021**, 14, e003179	5.2	1
675	Genetics of hypertriglyceridemia and atherosclerosis. *Current Opinion in Cardiology*, **2021**, 36, 264-271	2.1	14
674	Editorial comment: hazards of interpreting genetic reports. *Current Opinion in Lipidology*, **2021**, 32, 81-82	4.4	1
673	Cardiac ryanodine receptor calcium release deficiency syndrome. *Science Translational Medicine*, **2021**, 13,	17.5	18
672	Genetic Predictor to Identify Individuals With High Lipoprotein(a) Concentrations. *Circulation Genomic and Precision Medicine*, **2021**, 14, e003182	5.2	4
671	Volanesorsen for treatment of familial chylomicronemia syndrome. *Expert Review of Cardiovascular Therapy*, **2021**, 19, 685-693	2.5	5
670	2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. *Canadian Journal of Cardiology*, **2021**, 37, 1129-1150	3.8	62
669	Comment on "A New Allelic Variant in the PANK2 Gene in a Patient with Incomplete HARP Syndrome". *Journal of Movement Disorders*, **2021**, 14, 254-255	2.9	
668	Variation in biomarker levels of metals, persistent organic pollutants, and omega-3 fatty acids in association with genetic polymorphisms among Inuit in Nunavik, Canada. *Environmental Research*, **2021**, 200, 111393	7.9	3
667	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. *European Heart Journal*, **2021**,	9.5	35
666	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). *Lancet, The*, **2021**, 398, 1713-1725	40	14
665	Contribution of rare variant associations to neurodegenerative disease presentation. *Npj Genomic Medicine*, **2021**, 6, 80	6.2	1
664	Incidence, predictors and patterns of care of patients with very severe hypertriglyceridemia in Ontario, Canada: a population-based cohort study. *Lipids in Health and Disease*, **2021**, 20, 98	4.4	2
663	CREBH normalizes dyslipidemia and halts atherosclerosis in diabetes by decreasing circulating remnant lipoproteins. *Journal of Clinical Investigation*, **2021**, 131,	15.9	3
662	Association of apolipoprotein E variation with cognitive impairment across multiple neurodegenerative diagnoses. *Neurobiology of Aging*, **2021**, 105, 378.e1-378.e9	5.6	1

661	Familial Hypercholesterolemia-Risk-Score: A New Score Predicting Cardiovascular Events and Cardiovascular Mortality in Familial Hypercholesterolemia. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2021**, 41, 2632-2640	9.4	6
660	Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. *Nature Genetics*, **2021**, 53, 128-134	36.3	35
659	Landscape of Lipid Management Following an Acute Coronary Syndrome Event: Survey of Canadian Specialists. *CJC Open*, **2020**, 2, 625-631	2	0
658	Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. *Canadian Journal of Cardiology*, **2020**, 36, 596-624	3.8	139
657	Molecular mechanism linking a novel PCSK9 copy number variant to severe hypercholesterolemia. *Atherosclerosis*, **2020**, 304, 39-43	3.1	1
656	Parkinson's Disease, NOTCH3 Genetic Variants, and White Matter Hyperintensities. *Movement Disorders*, **2020**, 35, 2090-2095	7	8
655	Tangier disease: update for 2020. *Current Opinion in Lipidology*, **2020**, 31, 80-84	4.4	13
654	Loss-of-Function Variants in Patients With Severe Hypertriglyceridemia. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2020**, 40, 1935-1941	9.4	9
653	Six years' experience with LipidSeq: clinical and research learnings from a hybrid, targeted sequencing panel for dyslipidemias. *BMC Medical Genomics*, **2020**, 13, 23	3.7	23
652	Intermittent chylomicronemia caused by intermittent GPIHBP1 autoantibodies. *Journal of Clinical Lipidology*, **2020**, 14, 197-200	4.9	5
651	The polygenic nature of mild-to-moderate hypertriglyceridemia. *Journal of Clinical Lipidology*, **2020**, 14, 28-34.e2	4.9	21
650	A tip of the CAP1 to cholesterol metabolism. *European Heart Journal*, **2020**, 41, 253-254	9.5	3
649	The Canadian Consensus Working Group□ Approach to Identifying and Managing Statin-Associated Muscle and Other Symptoms. *Contemporary Cardiology*, **2020**, 137-150	0.1	
648	Pediatric Dyslipidemia-Beyond Familial Hypercholesterolemia. *Canadian Journal of Cardiology*, **2020**, 36, 1362-1371	3.8	3
647	Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association. *Journal of Clinical Lipidology*, **2020**, 14, 398-413	4.9	29
646	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. *European Heart Journal*, **2020**, 41, 2313-2330	9.5	301
645	LDL cholesterol: lower, faster, younger?. *Lancet Diabetes and Endocrinology,the*, **2020**, 8, 5-7	18.1	4
644	Clinical review on triglycerides. *European Heart Journal*, **2020**, 41, 99-109c	9.5	118

643	Annual Report on Sex in Preclinical Studies: Publications in 2018. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2020**, 40, e1-e9	9.4	4
642	No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels. *Atherosclerosis*, **2020**, 311, 13-19	3.1	14
641	Failure of cosegregation between a rare STAP1 missense variant and hypercholesterolemia. *Journal of Clinical Lipidology*, **2020**, 14, 636-638	4.9	2
640	Can genetic testing help in the management of dyslipidaemias?. *Current Opinion in Lipidology*, **2020**, 31, 187-193	4.4	3
639	A cautionary tale: Is this APOB whole-gene duplication actually pathogenic?. *Journal of Clinical Lipidology*, **2020**, 14, 631-635	4.9	1
638	Multisystem Progeroid Syndrome With Lipodystrophy, Cardiomyopathy, and Nephropathy Due to an p.R349W Variant. *Journal of the Endocrine Society*, **2020**, 4, bvaa104	0.4	1
637	Familial Chylomicronemia Syndrome With a Novel Homozygous LPL Mutation Identified in Three Siblings in Their 50s. *Annals of Internal Medicine*, **2020**, 172, 500-502	8	0
636	Regression of Xanthelasmas With Statin Treatment in a Normolipidemic Patient. *Annals of Internal Medicine*, **2020**, 172, 701-702	8	0
635	Genetics of Hypertriglyceridemia. *Frontiers in Endocrinology*, **2020**, 11, 455	5.7	41
634	Insulin's centenary: the birth of an idea. *Lancet Diabetes and Endocrinology,the*, **2020**, 8, 971-977	18.1	20
633	2019 George Lyman Duff Memorial Lecture: Three Decades of Examining DNA in Patients With Dyslipidemia. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2020**, 40, 1970-1981	9.4	9
632	Polygenic Contribution to Low-Density Lipoprotein Cholesterol Levels and Cardiovascular Risk in Monogenic Familial Hypercholesterolemia. *Circulation Genomic and Precision Medicine*, **2020**, 13, 515-523	5.2	13
631	A novel homozygous variant in REN in a family presenting with classic features of disorders involving the renin-angiotensin pathway, without renal tubular dysgenesis. *American Journal of Medical Genetics, Part A*, **2020**, 182, 2284-2290	2.5	1
630	Dyslipidemia Management in Adults With Diabetes. *Canadian Journal of Diabetes*, **2020**, 44, 53-60	2.1	19
629	Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. *Lancet Diabetes and Endocrinology,the*, **2020**, 8, 50-67	18.1	48
628	Apolipoprotein B and PNPLA3 Double Heterozygosity in a Father-Son Pair With Advanced Nonalcoholic Fatty Liver Disease. *Hepatology*, **2020**, 71, 383-385	11.2	1
627	Experimental Therapeutics for Challenging Clinical Care of a Patient with an Extremely Rare Homozygous Mutation. *Case Reports in Endocrinology*, **2020**, 2020, 1865489	1.2	3
626	Practical definitions of severe versus familial hypercholesterolaemia and hypertriglyceridaemia for adult clinical practice. *Lancet Diabetes and Endocrinology,the*, **2019**, 7, 880-886	18.1	14

625	Genetic Determinants of Myocardial Infarction Risk in Familial Hypercholesterolemia. *CJC Open*, **2019**, 1, 225-230	2	4
624	Prediction of Familial Hypercholesterolemia in Patients at High Atherosclerotic Cardiovascular Disease Risk Using a Recently Validated Algorithm. *CJC Open*, **2019**, 1, 190-197	2	2
623	Partial deletions: rare copy-number variants contributing towards severe hypertriglyceridemia. *Journal of Lipid Research*, **2019**, 60, 1953-1958	6.3	10
622	Genetic and epigenetic study of an Alzheimer's disease family with monozygotic triplets. *Brain*, **2019**, 142, 3375-3381	11.2	6
621	Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1). *American Journal of Cardiology*, **2019**, 124, 1876-1880	3	16
620	Severe Combined Dyslipidemia With a Complex Genetic Basis. *Journal of Investigative Medicine High Impact Case Reports*, **2019**, 7, 2324709619877050	1.2	2
619	Chylomicronemia: Differences between familial chylomicronemia syndrome and multifactorial chylomicronemia. *Atherosclerosis*, **2019**, 283, 137-142	3.1	34
618	Lipid-Lowering Agents. *Circulation Research*, **2019**, 124, 386-404	15.7	87
617	Cholesterol-Lowering Agents. *Circulation Research*, **2019**, 124, 364-385	15.7	25
616	Genetic Variation in the Ontario Neurodegenerative Disease Research Initiative. *Canadian Journal of Neurological Sciences*, **2019**, 46, 491-498	1	5
615	Efficacy of Evolocumab in Monogenic vs Polygenic Hypercholesterolemia. *CJC Open*, **2019**, 1, 115-118	2	6
614	Targeted next generation sequencing as a tool for precision medicine. *BMC Medical Genomics*, **2019**, 12, 81	3.7	26
613	Clinical Utility and Practical Considerations of a Coronary Artery Disease Genetic Risk Score. *CJC Open*, **2019**, 1, 69-75	2	3
612	Atypical familial dysbetalipoproteinemia associated with high polygenic cholesterol and triglyceride scores treated with ezetimibe and evolocumab. *Journal of Clinical Lipidology*, **2019**, 13, 411-414	4.9	4
611	A Single-dose, Comparative Bioavailability Study of a Formulation containing OM3 as Phospholipid and Free Fatty Acid to an Ethyl Ester Formulation in the Fasting and Fed States. *Clinical Therapeutics*, **2019**, 41, 426-444	3.5	11
610	The complex molecular genetics of familial hypercholesterolaemia. *Nature Reviews Cardiology*, **2019**, 16, 9-20	14.8	112
609	Targeted sequencing reveals expanded genetic diversity of human transfer RNAs. *RNA Biology*, **2019**, 16, 1574-1585	4.8	9
608	Bioinformatic detection of copy number variation in HNF4A causing maturity onset diabetes of the young. *Clinical Genetics*, **2019**, 96, 376-377	4	2

607	Copy Number Variation in GCK in Patients With Maturity-Onset Diabetes of the Young. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 3428-3436	5.6	7
606	Ischemic Event Reduction and Triglycerides. *Journal of the American College of Cardiology*, **2019**, 74, 1848-1849	18.3	1
605	Ankyrin-B dysfunction predisposes to arrhythmogenic cardiomyopathy and is amenable to therapy. *Journal of Clinical Investigation*, **2019**, 129, 3171-3184	15.9	23
604	27-OR: Simplifying Detection of Large Scale Deletions Causing MODY5. *Diabetes*, **2019**, 68, 27-OR	0.9	
603	Progress in finding pathogenic DNA copy number variations in dyslipidemia. *Current Opinion in Lipidology*, **2019**, 30, 63-70	4.4	11
602	Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles. *Journal of the Endocrine Society*, **2019**, 3, 2397-2410	0.4	18
601	Evaluation of OM3-PL/FFA Pharmacokinetics After Single and Multiple Oral Doses in Healthy Volunteers. *Clinical Therapeutics*, **2019**, 41, 2500-2516	3.5	2
600	The evolution of genetic-based risk scores for lipids and cardiovascular disease. *Current Opinion in Lipidology*, **2019**, 30, 71-81	4.4	32
599	Cannabis effects on lipoproteins. *Current Opinion in Lipidology*, **2019**, 30, 140-146	4.4	2
598	GPIHBP1 autoantibody syndrome during interferon α treatment. *Journal of Clinical Lipidology*, **2019**, 13, 62-69	4.9	9
597	The role of genetic testing in dyslipidaemia. *Pathology*, **2019**, 51, 184-192	1.6	25
596	Update on the diagnosis, treatment and management of rare genetic lipid disorders. *Pathology*, **2019**, 51, 193-201	1.6	11
595	Cholesterol Lowering and Prevention of Stroke. *Stroke*, **2019**, 50, 537-541	6.7	13
594	Severe hypertriglyceridemia is primarily polygenic. *Journal of Clinical Lipidology*, **2019**, 13, 80-88	4.9	85
593	Extreme hypertriglyceridemia: Genetic diversity, pancreatitis, pregnancy, and prevalence. *Journal of Clinical Lipidology*, **2019**, 13, 89-99	4.9	19
592	Complex effects of laminopathy mutations on nuclear structure and function. *Clinical Genetics*, **2019**, 95, 199-209	4	16
591	Tools for Enhancement and Quality Improvement of Peer Assessment and Clinical Care in Endocrinology and Metabolism. *Journal of Clinical Densitometry*, **2019**, 22, 125-149	3.5	1
590	Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. *Canadian Journal of Cardiology*, **2018**, 34, 506-525	3.8	348

589	Can We Eliminate Low-Density Lipoprotein Cholesterol-Related Cardiovascular Events Through More Aggressive Primary Prevention Therapy?. *Canadian Journal of Cardiology*, **2018**, 34, 546-551	3.8	2
588	Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease. *Journal of Visualized Experiments*, **2018**,	1.6	14
587	Clinical and biochemical features of different molecular etiologies of familial chylomicronemia. *Journal of Clinical Lipidology*, **2018**, 12, 920-927.e4	4.9	59
586	Dyslipidemia. *Canadian Journal of Diabetes*, **2018**, 42 Suppl 1, S178-S185	2.1	26
585	Genetic polymorphisms are associated with exposure biomarkers for metals and persistent organic pollutants among Inuit from the Inuvialuit Settlement Region, Canada. *Science of the Total Environment*, **2018**, 634, 569-578	10.2	4
584	A novel mutation in GPIHBP1 causes familial chylomicronemia syndrome. *Journal of Clinical Lipidology*, **2018**, 12, 506-510	4.9	5
583	Whole genome sequencing in the clinic: empowerment or too much information?. *Cmaj*, **2018**, 190, E124-E125	3.5	10
582	The Atherogenic Dyslipidemia Complex and Novel Approaches to Cardiovascular Disease Prevention in Diabetes. *Canadian Journal of Cardiology*, **2018**, 34, 595-604	3.8	37
581	Nutraceuticals in 2017: Nutraceuticals in endocrine disorders. *Nature Reviews Endocrinology*, **2018**, 14, 68-70	15.2	5
580	Role of DNA copy number variation in dyslipidemias. *Current Opinion in Lipidology*, **2018**, 29, 125-132	4.4	24
579	Polygenic influences on dyslipidemias. *Current Opinion in Lipidology*, **2018**, 29, 133-143	4.4	42
578	Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. *European Heart Journal*, **2018**, 39, 2526-2539	9.5	156
577	Complex genetic architecture in severe hypobetalipoproteinemia. *Lipids in Health and Disease*, **2018** , 17, 48	4.4	10
576	A Novel Generalized Lipodystrophy-Associated Progeroid Syndrome Due to Recurrent Heterozygous LMNA p.T10I Mutation. *Journal of Clinical Endocrinology and Metabolism*, **2018**, 103, 1005-1014	5.6	37
575	Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe. *Clinical Chemistry*, **2018**, 64, 355-362	5.5	32
574	Whole-Gene Duplication of PCSK9 as a Novel Genetic Mechanism for Severe Familial Hypercholesterolemia. *Canadian Journal of Cardiology*, **2018**, 34, 1316-1324	3.8	23
573	The Evolving Future of PCSK9 Inhibitors. *Journal of the American College of Cardiology*, **2018**, 72, 314-329	15.1	94
572	A De Novo Mutation Associated With Mandibular Hypoplasia, Deafness, Progeroid Features, and Lipodystrophy Syndrome in a Family With Werner Syndrome. *Journal of Investigative Medicine High Impact Case Reports*, **2018**, 6, 2324709618786770	1.2	6

571	Ezetimibe prescriptions in older Canadian adults after an acute myocardial infarction: a population-based cohort study. *Lipids in Health and Disease*, **2018**, 17, 8	4.4	6
570	Variants at the APOE /C1/C2/C4 Locus Modulate Cholesterol Efflux Capacity Independently of High-Density Lipoprotein Cholesterol. *Journal of the American Heart Association*, **2018**, 7, e009545	6	14
569	Large-scale deletions of the gene in patients with hypoalphalipoproteinemia. *Journal of Lipid Research*, **2018**, 59, 1529-1535	6.3	16
568	OPTN p.Met468Arg and ATXN2 intermediate length polyQ extension in families with C9orf72 mediated amyotrophic lateral sclerosis and frontotemporal dementia. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, **2018**, 177, 75-85	3.5	10
567	Food Effect on Rosuvastatin Disposition and Low-Density Lipoprotein Cholesterol. *Clinical Pharmacology and Therapeutics*, **2018**, 104, 525-533	6.1	8
566	The association between hypercholesterolemia and sitosterolemia, and report of a sitosterolemia kindred. *Journal of Clinical Lipidology*, **2018**, 12, 152-161	4.9	39
565	HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology. *Nature Reviews Cardiology*, **2018**, 15, 9-19	14.8	65
564	A Young Male with Parafibromin-Deficient Parathyroid Carcinoma Due to a Rare Germline HRPT2/CDC73 Mutation. *Endocrine Pathology*, **2018**, 29, 374-379	4.2	6
563	Whole-exome sequencing identifies a novel insertion in an Ontario family with brachydactyly type A1. *SAGE Open Medical Case Reports*, **2018**, 6, 2050313X18818711	0.7	4
562	Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018. *Canadian Journal of Cardiology*, **2018**, 34, 1553-1563	3.8	58
561	Multiple Symmetric Lipomatosis (Madelung Disease) in a Large Canadian Family With the Mitochondrial c.8344A>G Variant. *Journal of Investigative Medicine High Impact Case Reports*, **2018**, 6, 2324709618802867	1.2	9
560	Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry. *Atherosclerosis*, **2018**, 277, 419-424	3.1	10
559	Unusual genetic variants associated with hypercholesterolemia in Argentina. *Atherosclerosis*, **2018**, 277, 256-261	3.1	12
558	Reporting Sex and Sex Differences in Preclinical Studies. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2018**, 38, e171-e184	9.4	6
557	Recent Highlights of ATVB. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2018**, 38, e185-e197	9.4	3
556	ClinVar database of global familial hypercholesterolemia-associated DNA variants. *Human Mutation* , **2018**, 39, 1631-1640	4.7	55
555	Genetic and secondary causes of severe HDL deficiency and cardiovascular disease. *Journal of Lipid Research*, **2018**, 59, 2421-2435	6.3	25
554	Response by Daugherty et al to Letter Regarding Article, "Consideration of Sex Differences in Design and Reporting of Experimental Arterial Pathology Studies: A Statement From the Council". *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2018**, 38, e101-e102	9.4	2

553	Simplified Canadian Definition for Familial Hypercholesterolemia. *Canadian Journal of Cardiology*, **2018**, 34, 1210-1214	3.8	36
552	Co-occurrence of heterozygous CREB3L3 and APOA5 nonsense variants and polygenic risk in a patient with severe hypertriglyceridemia exacerbated by estrogen administration. *Journal of Clinical Lipidology*, **2018**, 12, 1146-1150	4.9	3
551	Heterozygous familial hypercholesterolemia presenting as chylomicronemia syndrome. *Journal of Clinical Lipidology*, **2017**, 11, 294-296	4.9	5
550	Estrogen-associated severe hypertriglyceridemia with pancreatitis. *Journal of Clinical Lipidology*, **2017**, 11, 297-300	4.9	14
549	Genetics for the Identification of Lipid Targets Beyond PCSK9. *Canadian Journal of Cardiology*, **2017** , 33, 334-342	3.8	7
548	Functional foods and dietary supplements for the management of dyslipidaemia. *Nature Reviews Endocrinology*, **2017**, 13, 278-288	15.2	110
547	Barriers to the Implementation of Lipoprotein Apheresis in Canada. *Canadian Journal of Cardiology*, **2017**, 33, 409-411	3.8	5
546	Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. *Canadian Journal of Cardiology*, **2017**, 33, 557-576	3.8	205
545	Clinical utility gene card for: Sitosterolaemia. *European Journal of Human Genetics*, **2017**, 25,	5.3	9
544	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. *European Heart Journal*, **2017**, 38, 2459-2472	9.5	1267
543	Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants. *Current Opinion in Lipidology*, **2017**, 28, 161-169	4.4	45
542	PCSK9 inhibitors: smooth sailing or a little turbulence ahead?. *Lancet Diabetes and Endocrinology,the*, **2017**, 5, 490-492	18.1	1
541	Insulin affordability. *Lancet Diabetes and Endocrinology,the*, **2017**, 5, 324	18.1	2
540	Lack of MTTP Activity in Pluripotent Stem Cell-Derived Hepatocytes and Cardiomyocytes Abolishes apoB Secretion and Increases Cell Stress. *Cell Reports*, **2017**, 19, 1456-1466	10.6	24
539	Investigated treatments for lipoprotein lipase deficiency and related metabolic disorders. *Expert Opinion on Orphan Drugs*, **2017**, 5, 411-420	1.1	
538	Recent advances in genetic testing for familial hypercholesterolemia. *Expert Review of Molecular Diagnostics*, **2017**, 17, 641-651	3.8	42
537	Genetics of Triglycerides and the Risk of Atherosclerosis. *Current Atherosclerosis Reports*, **2017**, 19, 31	6	71
536	Clinical utility gene card for: Tangier disease. *European Journal of Human Genetics*, **2017**, 25,	5.3	6

535	Lomitapide for the treatment of hypercholesterolemia. *Expert Opinion on Pharmacotherapy*, **2017**, 18, 1261-1268	4	29
534	Treatment of Severe Hypercholesterolemia in a Woman With Advanced Primary Sclerosing Cholangitis. *JAMA Cardiology*, **2017**, 2, 575-576	16.2	1
533	A truncating mutation in CEP55 is the likely cause of MARCH, a novel syndrome affecting neuronal mitosis. *Journal of Medical Genetics*, **2017**, 54, 490-501	5.8	30
532	The Ontario Neurodegenerative Disease Research Initiative (ONDRI). *Canadian Journal of Neurological Sciences*, **2017**, 44, 196-202	1	44
531	Identification and Characterization of Trimethylamine-N-oxide Uptake and Efflux Transporters. *Molecular Pharmaceutics*, **2017**, 14, 310-318	5.6	37
530	KMT2D p.Gln3575His segregating in a family with autosomal dominant choanal atresia strengthens the Kabuki/CHARGE connection. *American Journal of Medical Genetics, Part A*, **2017**, 173, 183-189	2.5	14
529	PCSK9 inhibition and diabetes: turning to Mendel for clues. *Lancet Diabetes and Endocrinology,the*, **2017**, 5, 78-79	18.1	2
528	Recent Advances in the Genetics of Atherothrombotic Disease and Its Determinants. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2017**, 37, e158-e166	9.4	6
527	The apolipoprotein C-III (Gln38Lys) variant associated with human hypertriglyceridemia is a gain-of-function mutation. *Journal of Lipid Research*, **2017**, 58, 2188-2196	6.3	25
526	ARHGEF28 p.Lys280Metfs40Ter in an amyotrophic lateral sclerosis family with a C9orf72 expansion. *Neurology: Genetics*, **2017**, 3, e190	3.8	4
525	Polygenic determinants in extremes of high-density lipoprotein cholesterol. *Journal of Lipid Research*, **2017**, 58, 2162-2170	6.3	33
524	Use of next-generation sequencing to detect gene copy number variation in familial hypercholesterolemia. *Journal of Lipid Research*, **2017**, 58, 2202-2209	6.3	53
523	Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia. *Circulation*, **2017**, 136, 332-335	16.7	63
522	Polygenic Risk for Hypertriglyceridemia Can Mimic a Major Monogenic Mutation. *Annals of Internal Medicine*, **2017**, 167, 360-361	8	16
521	Clinical Validation of Copy Number Variant Detection from Targeted Next-Generation Sequencing Panels. *Journal of Molecular Diagnostics*, **2017**, 19, 905-920	5.1	75
520	Statin therapy: time for a precision medicine approach?. *Expert Review of Precision Medicine and Drug Development*, **2017**, 2, 187-192	1.6	0
519	Familial hypercholesterolaemia. *Nature Reviews Disease Primers*, **2017**, 3, 17093	51.1	190
518	PCSK9: Regulation and Target for Drug Development for Dyslipidemia. *Annual Review of Pharmacology and Toxicology*, **2017**, 57, 223-244	17.9	49

517	Fatty liver in a non-obese patient. *Paediatrics and Child Health*, **2017**, 22, 59-60	0.7	1
516	Motor Phenotype in Neurodegenerative Disorders: Gait and Balance Platform Study Design Protocol for the Ontario Neurodegenerative Research Initiative (ONDRI). *Journal of Alzheimerks Disease*, **2017**, 59, 707-721	4.3	40
515	A Novel APOC2 Missense Mutation Causing Apolipoprotein C-II Deficiency With Severe Triglyceridemia and Pancreatitis. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 1454-1457	5.6	24
514	Identification of a novel synaptic protein, TMTC3, involved in periventricular nodular heterotopia with intellectual disability and epilepsy. *Human Molecular Genetics*, **2017**, 26, 4278-4289	5.6	25
513	Familial partial lipodystrophy presenting as metabolic syndrome. *Journal of Clinical Lipidology*, **2016** , 10, 1488-1491	4.9	19
512	Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2016**, 36, 2439-2445	9.4	130
511	Genetic Confirmation Rate in Clinically Suspected Maturity-Onset Diabetes of the Young. *Canadian Journal of Diabetes*, **2016**, 40, 555-560	2.1	14
510	2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. *Canadian Journal of Cardiology*, **2016**, 32, 1263-1282	3.8	543
509	Lomitapide for the treatment of hypertriglyceridemia. *Expert Opinion on Investigational Drugs*, **2016** , 25, 1457-1463	5.9	16
508	Complying With the National Institutes of Health Guidelines and Principles for Rigor and Reproducibility: Refutations. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2016**, 36, 1303-4	9.4	12
507	Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol. *Diabetes*, **2016**, 65, 1767-78	0.9	104
506	Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. *Lancet Diabetes and Endocrinology,the*, **2016**, 4, 850-61	18.1	215
505	A tale of 2 cousins: An atypical and a typical case of abetalipoproteinemia. *Journal of Clinical Lipidology*, **2016**, 10, 1030-1034	4.9	7
504	A novel ICK mutation causes ciliary disruption and lethal endocrine-cerebro-osteodysplasia syndrome. *Cilia*, **2016**, 5, 8	5.5	29
503	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). *Canadian Journal of Cardiology*, **2016**, 32, S35-65	3.8	138
502	Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine?. *Current Atherosclerosis Reports*, **2016**, 18, 24	6	15
501	Proprietary Considerations in the Use of Cardiovascular Genetic Data. *Canadian Journal of Cardiology*, **2016**, 32, 1297-1299	3.8	0
500	Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. *Canadian Journal of Cardiology*, **2016**, 32, 569-88	3.8	314

499	Statin Safety in Chinese: A Population-Based Study of Older Adults. *PLoS ONE*, **2016**, 11, e0150990	3.7	11
498	Combined hyperlipidemia: familial but not (usually) monogenic. *Current Opinion in Lipidology*, **2016**, 27, 131-40	4.4	46
497	Whole-genome sequencing in French Canadians from Quebec. *Human Genetics*, **2016**, 135, 1213-1221	6.3	13
496	New oral agents for treating dyslipidemia. *Current Opinion in Lipidology*, **2016**, 27, 579-584	4.4	8
495	Genetics of Lipid and Lipoprotein Disorders and Traits. *Current Genetic Medicine Reports*, **2016**, 4, 130-141	1.2	43
494	The ONDRISeq panel: custom-designed next-generation sequencing of genes related to neurodegeneration. *Npj Genomic Medicine*, **2016**, 1, 16032	6.2	17
493	Targeted exonic sequencing of GWAS loci in the high extremes of the plasma lipids distribution. *Atherosclerosis*, **2016**, 250, 63-8	3.1	9
492	Applying Atherosclerotic Risk Prevention Guidelines to Elderly Patients: A Bridge Too Far?. *Canadian Journal of Cardiology*, **2016**, 32, 598-602	3.8	1
491	Clinical utility gene card for: Familial hypobetalipoproteinaemia (APOB)--Update 2014. *European Journal of Human Genetics*, **2015**, 23,	5.3	6
490	Cardiology patient page. Statin intolerance. *Circulation*, **2015**, 131, e389-91	16.7	41
489	An siRNA-based functional genomics screen for the ´identification of regulators of ciliogenesis and ciliopathy´genes. *Nature Cell Biology*, **2015**, 17, 1074-1087	23.4	140
488	Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel Disease. *Digestive Diseases and Sciences*, **2015**, 60, 3620-30	4	39
487	The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. *Canadian Journal of Cardiology*, **2015**, 31, 549-68	3.8	222
486	Congenital sucrase-isomaltase deficiency: identification of a common Inuit founder mutation. *Cmaj*, **2015**, 187, 102-107	3.5	17
485	Common low-density lipoprotein receptor p.G116S variant has a large effect on plasma low-density lipoprotein cholesterol in circumpolar inuit populations. *Circulation: Cardiovascular Genetics*, **2015**, 8, 100-5		7
484	Ezetimibe: rescued by randomization (clinical and mendelian). *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, e13-5	9.4	15
483	Ezetimibe plus simvastatin for the treatment of hypercholesterolemia. *Expert Opinion on Pharmacotherapy*, **2015**, 16, 1255-62	4	11
482	Targeted next-generation sequencing in monogenic dyslipidemias. *Current Opinion in Lipidology*, **2015**, 26, 103-13	4.4	78

481	HDL re-examined. *Current Opinion in Lipidology*, **2015**, 26, 127-32	4.4	28
480	Contribution of common non-synonymous variants in PCSK1 to body mass index variation and risk of obesity: a systematic review and meta-analysis with evidence from up to 331 175 individuals. *Human Molecular Genetics*, **2015**, 24, 3582-94	5.6	34
479	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. *European Heart Journal*, **2015**, 36, 2425-37	9.5	430
478	Primary Hypertriglyceridemia. *Contemporary Endocrinology*, **2015**, 205-220	0.3	1
477	Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, 2269-80	9.4	48
476	Clinical utility gene card for: Abetalipoproteinaemia--Update 2014. *European Journal of Human Genetics*, **2015**, 23,	5.3	6
475	Old gene, new phenotype: mutations in heparan sulfate synthesis enzyme, EXT2 leads to seizure and developmental disorder, no exostoses. *Journal of Medical Genetics*, **2015**, 52, 666-75	5.8	22
474	Trial Watch: Antisenses working overtime in lipids. *Nature Reviews Endocrinology*, **2015**, 11, 574-6	15.2	2
473	Microsomal Triglyceride Transfer Protein Transfers and Determines Plasma Concentrations of Ceramide and Sphingomyelin but Not Glycosylceramide. *Journal of Biological Chemistry*, **2015**, 290, 25863-75	5.4	39
472	The Genetics of Cardiovascular Disease in Canadian and International Aboriginal Populations. *Canadian Journal of Cardiology*, **2015**, 31, 1094-115	3.8	4
471	G-protein estrogen receptor as a regulator of low-density lipoprotein cholesterol metabolism: cellular and population genetic studies. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, 213-21	9.4	33
470	Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. *Nature*, **2015**, 518, 102-6	50.4	463
469	Refinement of variant selection for the LDL cholesterol genetic risk score in the diagnosis of the polygenic form of clinical familial hypercholesterolemia and replication in samples from 6 countries. *Clinical Chemistry*, **2015**, 61, 231-8	5.5	130
468	Simple genetics language as source of miscommunication between genetics researchers and potential research participants in informed consent documents. *Public Understanding of Science*, **2015**, 24, 751-66	3.1	9
467	The new dyslipidemia guidelines: what is the debate?. *Canadian Journal of Cardiology*, **2015**, 31, 605-12	3.8	32
466	Matching two independent cohorts validates DPH1 as a gene responsible for autosomal recessive intellectual disability with short stature, craniofacial, and ectodermal anomalies. *Human Mutation*, **2015**, 36, 1015-9	4.7	25
465	MG-107 Congenital sucrase-isomaltase deficiency: Identification of the common inuit founder mutation. *Journal of Medical Genetics*, **2015**, 52, A1.3-A2	5.8	
464	Severe Hypertriglyceridemia due to a novel p.Q240H mutation in the Lipoprotein Lipase gene. *Lipids in Health and Disease*, **2015**, 14, 102	4.4	6

463	MG-137 Autosomal recessive disorders are common in the old order amish population of southwestern ontario. *Journal of Medical Genetics*, **2015**, 52, A10.1-A10	5.8	
462	Novel therapeutics in hypertriglyceridemia. *Current Opinion in Lipidology*, **2015**, 26, 484-91	4.4	27
461	Validation of volumetric and single-slice MRI adipose analysis using a novel fully automated segmentation method. *Journal of Magnetic Resonance Imaging*, **2015**, 41, 233-41	5.6	40
460	Chylomicronaemia--current diagnosis and future therapies. *Nature Reviews Endocrinology*, **2015**, 11, 352-62	13.2	182
459	Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. *European Heart Journal*, **2015**, 36, 1012-22	9.5	770
458	Lipid Management in Diabetes with a Focus on Emerging Therapies. *Canadian Journal of Diabetes*, **2015**, 39 Suppl 5, S183-90	2.1	7
457	Autosomal-Recessive Intellectual Disability with Cerebellar Atrophy Syndrome Caused by Mutation of the Manganese and Zinc Transporter Gene SLC39A8. *American Journal of Human Genetics*, **2015**, 97, 886-93	11	125
456	Hypertriglyceridemia in the genomic era: a new paradigm. *Endocrine Reviews*, **2015**, 36, 131-47	27.2	90
455	A homozygous PMS2 founder mutation with an attenuated constitutional mismatch repair deficiency phenotype. *Journal of Medical Genetics*, **2015**, 52, 348-52	5.8	23
454	Loss-of-function mutations in ABCA1 and enhanced □cell secretory capacity in young adults. *Diabetes*, **2015**, 64, 193-9	0.9	26
453	The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. *Canadian Journal of Cardiology*, **2014**, 30, 485-501	3.8	198
452	Pharmacogenomics, lipid disorders, and treatment options. *Clinical Pharmacology and Therapeutics*, **2014**, 96, 36-47	6.1	20
451	Gene-centric meta-analyses for central adiposity traits in up to 57 412 individuals of European descent confirm known loci and reveal several novel associations. *Human Molecular Genetics*, **2014**, 23, 2498-510	5.6	22
450	The effect of infrequent low-dose rosuvastatin on the lipid profile. *Canadian Journal of Cardiology*, **2014**, 30, 1392-5	3.8	
449	Exome sequencing identifies NFS1 deficiency in a novel Fe-S cluster disease, infantile mitochondrial complex II/III deficiency. *Molecular Genetics & Genomic Medicine*, **2014**, 2, 73-80	2.3	41
448	Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations. *Journal of Medical Genetics*, **2014**, 51, 537-44	5.8	77
447	Exome sequencing: new insights into lipoprotein disorders. *Current Cardiology Reports*, **2014**, 16, 507	4.2	15
446	Mining the genome for lipid genes. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2014**, 1842, 1993-2009	6.9	25

445	Treatment of severe hypertriglyceridaemia--authors' reply. *Lancet Diabetes and Endocrinology,the*, **2014**, 2, 860-1	18.1	1
444	Inducing thyrotoxicosis in the liver to treat raised cholesterol. *Lancet Diabetes and Endocrinology,the*, **2014**, 2, 438-9	18.1	
443	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. *Lancet Diabetes and Endocrinology,the*, **2014**, 2, 655-66	18.1	357
442	N-of-1 (single-patient) trials for statin-related myalgia. *Annals of Internal Medicine*, **2014**, 160, 301-10	8	76
441	A novel MC4R mutation associated with childhood-onset obesity: A case report. *Paediatrics and Child Health*, **2014**, 19, 515-8	0.7	24
440	LipidSeq: a next-generation clinical resequencing panel for monogenic dyslipidemias. *Journal of Lipid Research*, **2014**, 55, 765-72	6.3	95
439	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. *European Heart Journal*, **2014**, 35, 2146-57	9.5	614
438	Linkage analysis and exome sequencing identify a novel mutation in KCTD7 in patients with progressive myoclonus epilepsy with ataxia. *Epilepsia*, **2014**, 55, e106-11	6.4	18
437	Exome sequencing as a diagnostic tool for pediatric-onset ataxia. *Human Mutation*, **2014**, 35, 45-9	4.7	72
436	A novel LIPE nonsense mutation found using exome sequencing in siblings with late-onset familial partial lipodystrophy. *Canadian Journal of Cardiology*, **2014**, 30, 1649-54	3.8	50
435	Partial lipodystrophy associated with muscular dystrophy of unknown genetic origin. *Muscle and Nerve*, **2014**, 49, 928-30	3.4	10
434	Canadian Cardiovascular Society position statement on familial hypercholesterolemia. *Canadian Journal of Cardiology*, **2014**, 30, 1471-81	3.8	71
433	Inheritance of rare functional GCKR variants and their contribution to triglyceride levels in families. *Human Molecular Genetics*, **2014**, 23, 5570-8	5.6	18
432	Severe hypertriglyceridemia with pancreatitis: thirteen years' treatment with lomitapide. *JAMA Internal Medicine*, **2014**, 174, 443-7	11.5	79
431	Progression to hepatitis and fibrosis secondary to lomitapide use--reply. *JAMA Internal Medicine*, **2014**, 174, 1522-3	11.5	3
430	Progress in genetics of plasma lipids. *Current Opinion in Lipidology*, **2014**, 25, 99-101	4.4	1
429	A common hypofunctional genetic variant of GPER is associated with increased blood pressure in women. *British Journal of Clinical Pharmacology*, **2014**, 78, 1441-52	3.8	28
428	Abetalipoproteinemia and homozygous hypobetalipoproteinemia: a framework for diagnosis and management. *Journal of Inherited Metabolic Disease*, **2014**, 37, 333-9	5.4	121

427	Infantile Sialic Acid Storage Disease: Two Unrelated Inuit Cases Homozygous for a Common Novel SLC17A5 Mutation. *JIMD Reports*, **2014**, 12, 79-84	1.9	6
426	Disorders of Lipoprotein Metabolism **2014**, 671-689		3
425	Omega-3 fatty acids, polymorphisms and lipid related cardiovascular disease risk factors in the Inuit population. *Nutrition and Metabolism*, **2013**, 10, 26	4.6	17
424	Intellectual disability associated with a homozygous missense mutation in THOC6. *Orphanet Journal of Rare Diseases*, **2013**, 8, 62	4.2	34
423	Lipoprotein and Lipid Metabolism **2013**, 1-33		2
422	Homozygous lamin A/C familial lipodystrophy R482Q mutation in autosomal recessive Emery Dreifuss muscular dystrophy. *Neuromuscular Disorders*, **2013**, 23, 265-8	2.9	18
421	Genetics 101 for cardiologists: rare genetic variants and monogenic cardiovascular disease. *Canadian Journal of Cardiology*, **2013**, 29, 18-22	3.8	9
420	Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. *Canadian Journal of Cardiology*, **2013**, 29, 1553-68	3.8	126
419	Dyslipidemia. *Canadian Journal of Diabetes*, **2013**, 37 Suppl 1, S110-6	2.1	13
418	Dyslipidemie. *Canadian Journal of Diabetes*, **2013**, 37, S484-S491	2.1	1
417	Western Database of Lipid Variants (WDLV): a catalogue of genetic variants in monogenic dyslipidemias. *Canadian Journal of Cardiology*, **2013**, 29, 934-9	3.8	19
416	A mutation in the serine protease TMPRSS4 in a novel pediatric neurodegenerative disorder. *Orphanet Journal of Rare Diseases*, **2013**, 8, 126	4.2	4
415	Genetics 100 for cardiologists: basics of genome-wide association studies. *Canadian Journal of Cardiology*, **2013**, 29, 10-7	3.8	27
414	Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. *Lancet, The*, **2013**, 381, 40-6	40	480
413	Detection of a novel frameshift mutation and regions with homozygosis within ARHGEF28 gene in familial amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2013**, 14, 444-51	3.6	27
412	HDL--is it too big to fail?. *Nature Reviews Endocrinology*, **2013**, 9, 308-12	15.2	22
411	Incremental lowering of low-density lipoprotein cholesterol with ezetimibe 20 mg vs 10 mg daily in patients receiving concomitant statin therapy. *Canadian Journal of Cardiology*, **2013**, 29, 1395-9	3.8	3
410	Recessive TRAPPC11 mutations cause a disease spectrum of limb girdle muscular dystrophy and myopathy with movement disorder and intellectual disability. *American Journal of Human Genetics*, **2013**, 93, 181-90	11	76

409	APOE p.Leu167del mutation in familial hypercholesterolemia. *Atherosclerosis*, **2013**, 231, 218-22	3.1	67
408	HDL deficiency due to a new insertion mutation (ApoA-INashua) and review of the literature. *Journal of Clinical Lipidology*, **2013**, 7, 169-73	4.9	15
407	Clinical equivalence of proprietary and generic atorvastatin in lipid clinic patients. *Canadian Journal of Cardiology*, **2013**, 29, 418-22	3.8	7
406	Efficacy and plasma drug concentrations with nondaily dosing of rosuvastatin. *Canadian Journal of Cardiology*, **2013**, 29, 915-9	3.8	9
405	The Metabolic Syndrome **2013**, 1006-1016		3
404	The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. *Canadian Journal of Cardiology*, **2013**, 29, 528-42	3.8	147
403	2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. *Canadian Journal of Cardiology*, **2013**, 29, 151-67	3.8	545
402	Genetic determinants of "cognitive impairment, no dementia". *Journal of Alzheimerks Disease*, **2013**, 33, 831-40	4.3	8
401	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. *European Heart Journal*, **2013**, 34, 3478-90a	9.5	1551
400	Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy. *Journal of Lipid Research*, **2013**, 54, 1980-7	6.3	7
399	Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. *Circulation: Cardiovascular Genetics*, **2013**, 6, 400-8		124
398	Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia. *Expert Opinion on Investigational Drugs*, **2013**, 22, 1411-23	5.9	18
397	Gene-diet interactions on plasma lipid levels in the Inuit population. *British Journal of Nutrition*, **2013**, 109, 953-61	3.6	48
396	Causal relationship between adiponectin and metabolic traits: a Mendelian randomization study in a multiethnic population. *PLoS ONE*, **2013**, 8, e66808	3.7	44
395	Hypertriglyceridemia. *Nutrients*, **2013**, 5, 981-1001	6.7	85
394	CETP Inhibitors: Will They Live up to Their Promise?. *Current Cardiovascular Risk Reports*, **2012**, 6, 4-11	0.9	
393	Niacin: another look at an underutilized lipid-lowering medication. *Nature Reviews Endocrinology*, **2012**, 8, 517-28	15.2	33
392	Allelic and phenotypic spectrum of plasma triglycerides. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2012**, 1821, 833-42	5	38

391	The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. *Canadian Journal of Cardiology*, **2012**, 28, 270-87	3.8	133
390	Excess of rare variants in non-genome-wide association study candidate genes in patients with hypertriglyceridemia. *Circulation: Cardiovascular Genetics*, **2012**, 5, 66-72		65
389	BRCA2 variants and cardiovascular disease in a multi-ethnic study. *BMC Medical Genetics*, **2012**, 13, 56	2.1	7
388	Clinical utility gene card for: Familial Hypobetalipoproteinaemia (APOB). *European Journal of Human Genetics*, **2012**, 20,	5.3	10
387	Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. *American Journal of Human Genetics*, **2012**, 91, 823-38	11	189
386	The application of gene therapy in lipid disorders: where are we now?. *Clinical Lipidology*, **2012**, 7, 419-429		1
385	Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib. *Drug Design, Development and Therapy*, **2012**, 6, 251-9	4.4	9
384	Familial hypobetalipoproteinemia-induced nonalcoholic steatohepatitis. *Case Reports in Gastroenterology*, **2012**, 6, 429-37	1	6
383	A shared founder mutation underlies restrictive dermopathy in Old Colony (Dutch-German) Mennonite and Hutterite patients in North America. *American Journal of Medical Genetics, Part A*, **2012**, 158A, 1229-32	2.5	9
382	The complex genetic basis of plasma triglycerides. *Current Atherosclerosis Reports*, **2012**, 14, 227-34	6	29
381	Transient infantile hypertriglyceridemia, fatty liver, and hepatic fibrosis caused by mutated GPD1, encoding glycerol-3-phosphate dehydrogenase 1. *American Journal of Human Genetics*, **2012**, 90, 49-60	11	58
380	Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. *American Journal of Human Genetics*, **2012**, 90, 410-25	11	214
379	Activation of peroxisome proliferator-activated receptor inhibits human macrophage foam cell formation and the inflammatory response induced by very low-density lipoprotein. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2012**, 32, 2919-28	9.4	41
378	Lipoprotein(a): more interesting than ever after 50 years. *Current Opinion in Lipidology*, **2012**, 23, 133-40	4.4	89
377	Clinical utility gene card for: Abetalipoproteinaemia. *European Journal of Human Genetics*, **2012**, 20,	5.3	30
376	Severe hypertriglyceridemia in pregnancy. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 2589-96	5.6	113
375	The oxysterol 24(s),25-epoxycholesterol attenuates human smooth muscle-derived foam cell formation via reduced low-density lipoprotein uptake and enhanced cholesterol efflux. *Journal of the American Heart Association*, **2012**, 1, e000810	6	18
374	Clinical and molecular characterization of a severe form of partial lipodystrophy expanding the phenotype of PPAR deficiency. *Journal of Lipid Research*, **2012**, 53, 1968-78	6.3	15

373	Gene-centric meta-analysis of lipid traits in African, East Asian and Hispanic populations. *PLoS ONE*, **2012**, 7, e50198	3.7	37
372	A novel mutation of apolipoprotein B in a French Canadian family with homozygous hypobetalipoproteinemia. *Journal of Clinical Lipidology*, **2011**, 5, 414-7	4.9	5
371	Clinical implications of direct-to-consumer genetic testing for cardiovascular disease risk. *Canadian Journal of Cardiology*, **2011**, 27, 682-4	3.8	4
370	The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. *Canadian Journal of Cardiology*, **2011**, 27, 415-433.e1-2	3.8	93
369	Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. *Canadian Journal of Cardiology*, **2011**, 27, 635-62	3.8	135
368	Transcriptional profiling of endocrine cerebro-osteodysplasia using microarray and next-generation sequencing. *PLoS ONE*, **2011**, 6, e25400	3.7	8
367	Genetic bases of hypertriglyceridemic phenotypes. *Current Opinion in Lipidology*, **2011**, 22, 247-53	4.4	90
366	Bias due to selection of rare variants using frequency in controls. *Nature Genetics*, **2011**, 43, 394-395	36.3	5
365	Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. *American Journal of Human Genetics*, **2011**, 88, 6-18	11	103
364	TMEM237 is mutated in individuals with a Joubert syndrome related disorder and expands the role of the TMEM family at the ciliary transition zone. *American Journal of Human Genetics*, **2011**, 89, 713-30	11	145
363	HNF1A G319S variant, active cigarette smoking and incident type 2 diabetes in Aboriginal Canadians: a population-based epidemiological study. *BMC Medical Genetics*, **2011**, 12, 1	2.1	25
362	Evaluation of adipose tissue volume quantification with IDEAL fat-water separation. *Journal of Magnetic Resonance Imaging*, **2011**, 34, 474-9	5.6	24
361	Sortilin: an unusual suspect in cholesterol metabolism: from GWAS identification to in vivo biochemical analyses, sortilin has been identified as a novel mediator of human lipoprotein metabolism. *BioEssays*, **2011**, 33, 430-7	4.1	32
360	Lipid modification in the elderly using the combination of a statin and a cholesterol absorption inhibitor. *Expert Opinion on Pharmacotherapy*, **2011**, 12, 675-8	4	1
359	The transcription factor cyclic AMP-responsive element-binding protein H regulates triglyceride metabolism. *Nature Medicine*, **2011**, 17, 812-5	50.5	147
358	An increased burden of common and rare lipid-associated risk alleles contributes to the phenotypic spectrum of hypertriglyceridemia. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2011**, 31, 1916-26	9.4	73
357	Genetic risk factors for stroke in the genome-wide association era. *Expert Opinion on Medical Diagnostics*, **2011**, 5, 75-84		
356	Genetic determinants of plasma triglycerides. *Journal of Lipid Research*, **2011**, 52, 189-206	6.3	187

355	Biological, clinical and population relevance of 95 loci for blood lipids. *Nature*, **2010**, 466, 707-13	50.4	2742
354	Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. *Nature Genetics*, **2010**, 42, 684-7	36.3	365
353	Kinase mutations in human disease: interpreting genotype-phenotype relationships. *Nature Reviews Genetics*, **2010**, 11, 60-74	30.1	250
352	Rare ATGL haplotypes are associated with increased plasma triglyceride concentrations in the Greenland Inuit. *International Journal of Circumpolar Health*, **2010**, 69, 3-12	1.7	5
351	Association of apolipoprotein B with incident type 2 diabetes in an aboriginal Canadian population. *Clinical Chemistry*, **2010**, 56, 666-70	5.5	46
350	Extremes of unexplained variation as a phenotype: an efficient approach for genome-wide association studies of cardiovascular disease. *Circulation: Cardiovascular Genetics*, **2010**, 3, 215-21		44
349	APOC1 T45S polymorphism is associated with reduced obesity indices and lower plasma concentrations of leptin and apolipoprotein C-I in aboriginal Canadians. *Journal of Lipid Research*, **2010**, 51, 843-8	6.3	10
348	Genome-wide association studies of plasma lipids: have we reached the limit?. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2010**, 30, 2084-6	9.4	6
347	Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly. *Journal of Lipid Research*, **2010**, 51, 1201-7	6.3	44
346	Primary deficiency of microsomal triglyceride transfer protein in human abetalipoproteinemia is associated with loss of CD1 function. *Journal of Clinical Investigation*, **2010**, 120, 2889-99	15.9	64
345	Advances in genomic analysis of stroke: what have we learned and where are we headed?. *Stroke*, **2010**, 41, 825-32	6.7	64
344	Increased blood pressure and hyperdynamic cardiovascular responses in carriers of a common hyperfunctional variant of adenylyl cyclase 6. *Journal of Pharmacology and Experimental Therapeutics*, **2010**, 335, 451-7	4.7	17
343	Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a) in South Asians, Chinese, and European Caucasians. *Circulation: Cardiovascular Genetics*, **2010**, 3, 39-46		95
342	Phenomics. *Journal of Investigative Medicine*, **2010**, 58, 700-706	2.9	24
341	Translating genomic analyses into improved management of coronary artery disease. *Future Cardiology*, **2010**, 6, 507-21	1.3	5
340	Advances in stroke 2009: update on the genetics of stroke and cerebrovascular disease 2009. *Stroke*, **2010**, 41, e63-6	6.7	7
339	A translational view of the genetics of lipodystrophy and ectopic fat deposition. *Progress in Molecular Biology and Translational Science*, **2010**, 94, 159-96	4	11
338	Effects of intensive medical therapy on microemboli and cardiovascular risk in asymptomatic carotid stenosis. *Archives of Neurology*, **2010**, 67, 180-6		254

337	Mipomersen as a potential adjunctive therapy for hypercholesterolemia. *Expert Opinion on Pharmacotherapy*, **2010**, 11, 2569-72	4	15
336	Complete Apo AI deficiency in an Iraqi Mandaean family: case studies and review of the literature. *Journal of Clinical Lipidology*, **2010**, 4, 420-6	4.9	13
335	Proteinuria and severe mixed dyslipidemia associated with a novel APOAV gene mutation. *Journal of Clinical Lipidology*, **2010**, 4, 310-3	4.9	5
334	The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. *Canadian Journal of Cardiology*, **2010**, 26, 249-58	3.8	131
333	Genetic variation in hyaluronan metabolism loci is associated with plasma plasminogen activator inhibitor-1 concentration. *Blood*, **2010**, 116, 2160-3	2.2	7
332	Temtamy preaxial brachydactyly syndrome is caused by loss-of-function mutations in chondroitin synthase 1, a potential target of BMP signaling. *American Journal of Human Genetics*, **2010**, 87, 757-67	11	77
331	Assessing the association of the HNF1A G319S variant with C-reactive protein in Aboriginal Canadians: a population-based epidemiological study. *Cardiovascular Diabetology*, **2010**, 9, 39	8.7	7
330	Hepatic lipase deficiency in a Middle-Eastern-Arabic male. *BMJ Case Reports*, **2010**, 2010,	0.9	5
329	Phenomics: expanding the role of clinical evaluation in genomic studies. *Journal of Investigative Medicine*, **2010**, 58, 700-6	2.9	19
328	Carnitine palmitoyltransferase IA polymorphism P479L is common in Greenland Inuit and is associated with elevated plasma apolipoprotein A-I. *Journal of Lipid Research*, **2009**, 50, 1223-8	6.3	43
327	Comparison of gadofluorine-M and Gd-DTPA for noninvasive staging of atherosclerotic plaque stability using MRI. *Circulation: Cardiovascular Imaging*, **2009**, 2, 226-34	3.9	26
326	Enzyme-sensitive magnetic resonance imaging targeting myeloperoxidase identifies active inflammation in experimental rabbit atherosclerotic plaques. *Circulation*, **2009**, 120, 592-9	16.7	130
325	Replication of genetic associations with plasma lipoprotein traits in a multiethnic sample. *Journal of Lipid Research*, **2009**, 50, 1487-96	6.3	50
324	A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia. *Human Molecular Genetics*, **2009**, 18, 4189-94	5.6	77
323	Clinical field-strength MRI of amyloid plaques induced by low-level cholesterol feeding in rabbits. *Brain*, **2009**, 132, 1346-54	11.2	15
322	Update on the genetics of stroke and cerebrovascular disease 2008. *Stroke*, **2009**, 40, e289-91	6.7	2
321	Determination of lipoprotein(a) kringle repeat number from genomic DNA: copy number variation genotyping using qPCR. *Journal of Lipid Research*, **2009**, 50, 768-72	6.3	35
320	Multi-ethnic genetic association study of carotid intima-media thickness using a targeted cardiovascular SNP microarray. *Stroke*, **2009**, 40, 3173-9	6.7	29

319	Association of the novel cardiovascular risk factors paraoxonase 1 and cystatin C in type 2 diabetes. *Journal of Lipid Research*, **2009**, 50, 1216-22	6.3	22
318	Meta-analysis of the INSIG2 association with obesity including 74,345 individuals: does heterogeneity of estimates relate to study design?. *PLoS Genetics*, **2009**, 5, e1000694	6	54
317	Narrative review: statin-related myopathy. *Annals of Internal Medicine*, **2009**, 150, 858-68	8	298
316	Hypertriglyceridemia: phenomics and genomics. *Molecular and Cellular Biochemistry*, **2009**, 326, 35-43	4.2	41
315	G□□ique du syndrome m□abolique. *Bio Tribune Magazine*, **2009**, 30, 25-32		
314	Plasma lipoproteins: genetic influences and clinical implications. *Nature Reviews Genetics*, **2009**, 10, 109-21	30.1	304
313	A multiplex human syndrome implicates a key role for intestinal cell kinase in development of central nervous, skeletal, and endocrine systems. *American Journal of Human Genetics*, **2009**, 84, 134-47	11	47
312	A Multiplex Human Syndrome Implicates a Key Role for Intestinal Cell Kinase in Development of Central Nervous, Skeletal, and Endocrine Systems. *American Journal of Human Genetics*, **2009**, 84, 822	11	3
311	Cystathionine gamma-lyase: Clinical, metabolic, genetic, and structural studies. *Molecular Genetics and Metabolism*, **2009**, 97, 250-9	3.7	43
310	Predicting abdominal adipose tissue among women with familial partial lipodystrophy. *Metabolism: Clinical and Experimental*, **2009**, 58, 828-34	12.7	14
309	Predictive genetic testing for coronary artery disease. *Critical Reviews in Clinical Laboratory Sciences* , **2009**, 46, 343-60	9.4	11
308	Gene-gene and gene-environment interactions: new insights into the prevention, detection and management of coronary artery disease. *Genome Medicine*, **2009**, 1, 28	14.4	42
307	Triple X syndrome in a patient with partial lipodystrophy discovered using a high-density oligonucleotide microarray: a case report. *Journal of Medical Case Reports*, **2009**, 3, 8867	1.2	2
306	Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance. *Diabetes*, **2009**, 58, 2198-210	0.9	221
305	Novel LPL mutations associated with lipoprotein lipase deficiency: two case reports and a literature review. *Canadian Journal of Physiology and Pharmacology*, **2009**, 87, 151-60	2.4	60
304	Relationship of the ApoE polymorphism to plasma lipid traits among South Asians, Chinese, and Europeans living in Canada. *Atherosclerosis*, **2009**, 203, 192-200	3.1	30
303	Alternate day dosing of rosuvastatin: potential usefulness in statin-intolerant patients. *Canadian Journal of Cardiology*, **2009**, 25, 453	3.8	4
302	The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy. *Canadian Journal of Cardiology*, **2009**, 25, 287-98	3.8	97

301	2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. *Canadian Journal of Cardiology*, **2009**, 25, 567-79	3.8	567
300	Metabolic syndrome and its components as predictors of incident type 2 diabetes mellitus in an Aboriginal community. *Cmaj*, **2009**, 180, 617-24	3.5	48
299	The end of the road for CETP inhibitors after torcetrapib?. *Current Opinion in Cardiology*, **2009**, 24, 364-71	1.1	33
298	Lipid-altering gene variants and cardiovascular risk in the older population. *Clinical Lipidology*, **2009**, 4, 721-724		
297	Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. *Journal of Clinical Investigation*, **2009**, 119, 1042-50	15.9	144
296	Hoofbeats, zebras, and insights into insulin resistance. *Journal of Clinical Investigation*, **2009**, 119, 249-51	15.9	2
295	Genetics of Metabolic Syndrome and Genetic Lipodystrophies **2009**, 63-81		
294	The failure of torcetrapib: what have we learned?. *British Journal of Pharmacology*, **2008**, 154, 1379-81	8.6	35
293	Is raising HDL a futile strategy for atheroprotection?. *Nature Reviews Drug Discovery*, **2008**, 7, 143-55	64.1	111
292	Variation in Niemann-Pick C1-like 1 gene as a determinant of apolipoprotein B-100 kinetics and response to statin therapy in centrally obese men. *Clinical Endocrinology*, **2008**, 69, 45-51	3.4	14
291	Abetalipoproteinemia: two case reports and literature review. *Orphanet Journal of Rare Diseases*, **2008**, 3, 19	4.2	137
290	Familial hypobetalipoproteinemia due to a novel early stop mutation. *Journal of Clinical Lipidology*, **2008**, 2, 384-90	4.9	4
289	Heterozygous CAV1 frameshift mutations (MIM 601047) in patients with atypical partial lipodystrophy and hypertriglyceridemia. *Lipids in Health and Disease*, **2008**, 7, 3	4.4	104
288	Monogenic pediatric dyslipidemias: classification, genetics and clinical spectrum. *Molecular Genetics and Metabolism*, **2008**, 93, 282-94	3.7	59
287	Emerging antidyslipidemic drugs. *Expert Opinion on Emerging Drugs*, **2008**, 13, 363-81	3.7	14
286	The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. *Canadian Journal of Cardiology*, **2008**, 24, 465-75	3.8	69
285	Clinical and public health assessment of benefits and risks of statins in primary prevention of coronary events: resolved and unresolved issues. *Canadian Journal of Cardiology*, **2008**, 24, 293-300	3.8	13
284	Genetic testing for atherosclerosis risk: inevitability or pipe dream?. *Canadian Journal of Cardiology*, **2008**, 24, 851-4	3.8	8

283	Lipoprotein(a) is associated differentially with carotid stenosis, occlusion, and total plaque area. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2008**, 28, 1851-6	9.4	54
282	Association of the FABP2 T54 variant with plasma triglycerides and insulin resistance in a multiethnic population. *Clinical Chemistry*, **2008**, 54, 1742-4	5.5	5
281	Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency. *Journal of Lipid Research*, **2008**, 49, 349-57	6.3	52
280	APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia. *Nature Clinical Practice Cardiovascular Medicine*, **2008**, 5, 730-7		48
279	An unusual case of severe hypertriglyceridemia and splenomegaly. *Clinical Chemistry*, **2008**, 54, 606-10; discussion 610-1	5.5	8
278	Adipokines and incident type 2 diabetes in an Aboriginal Canadian [corrected] population: the Sandy Lake Health and Diabetes Project. *Diabetes Care*, **2008**, 31, 1410-5	14.6	65
277	Predictors of mammographic density: insights gained from a novel regression analysis of a twin study. *Cancer Epidemiology Biomarkers and Prevention*, **2008**, 17, 3474-81	4	45
276	Update on the genetics of stroke and cerebrovascular disease 2007. *Stroke*, **2008**, 39, 252-4	6.7	5
275	Microsomal triglyceride transfer protein inhibition-friend or foe?. *Nature Clinical Practice Cardiovascular Medicine*, **2008**, 5, 506-8		14
274	Uncloaking the genetic determinants of metabolic syndrome. *Journal of Nutrigenetics and Nutrigenomics*, **2008**, 1, 118-25		11
273	Polygenic determinants of severe hypertriglyceridemia. *Human Molecular Genetics*, **2008**, 17, 2894-9	5.6	101
272	Genetics of metabolic syndrome: is there a role for phenomics?. *Current Atherosclerosis Reports*, **2008**, 10, 201-8	6	28
271	Genetics of metabolic syndrome. *Current Diabetes Reports*, **2008**, 8, 141-8	5.6	41
270	Association between the FTO rs9939609 polymorphism and the metabolic syndrome in a non-Caucasian multi-ethnic sample. *Cardiovascular Diabetology*, **2008**, 7, 5	8.7	73
269	Prevalence of reproductive abnormalities among women with familial partial lipodystrophy. *Endocrine Practice*, **2008**, 14, 1126-32	3.2	16
268	Constructing Treatment Portfolios Using Affinity Propagation **2008**, 360-371		17
267	Alstrom syndrome (OMIM 203800): a case report and literature review. *Orphanet Journal of Rare Diseases*, **2007**, 2, 49	4.2	47
266	Efficacy and safety of pioglitazone in treatment of a patient with an atypical partial lipodystrophy syndrome. *Endocrine Practice*, **2007**, 13, 656-61	3.2	16

265	MRI of early- and late-stage arterial remodeling in a low-level cholesterol-fed rabbit model of atherosclerosis. *Journal of Magnetic Resonance Imaging*, **2007**, 26, 1010-9	5.6	11
264	Quantitative and qualitative differences in subcutaneous adipose tissue stores across lipodystrophy types shown by magnetic resonance imaging. *BMC Medical Imaging*, **2007**, 7, 3	2.9	21
263	Association between the -455T>C promoter polymorphism of the APOC3 gene and the metabolic syndrome in a multi-ethnic sample. *BMC Medical Genetics*, **2007**, 8, 80	2.1	33
262	Response to Landires et al.. *Clinical Genetics*, **2007**, 71, 594-596	4	1
261	Inherited lipodystrophies and the metabolic syndrome. *Clinical Endocrinology*, **2007**, 67, 479-84	3.4	11
260	Phenomics and lamins: from disease to therapy. *Experimental Cell Research*, **2007**, 313, 2134-43	4.2	19
259	Genetic forms of the cardiometabolic syndrome: what can they tell the clinician?. *Journal of the Cardiometabolic Syndrome*, **2007**, 2, 45-8		5
258	Peroxisome proliferator-activated receptor gamma polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes. *Journal of Diabetes and Its Complications*, **2007**, 21, 166-71	3.2	26
257	Missense mutations in APOB within the betaalpha1 domain of human APOB-100 result in impaired secretion of ApoB and ApoB-containing lipoproteins in familial hypobetalipoproteinemia. *Journal of Biological Chemistry*, **2007**, 282, 24270-83	5.4	58
256	Selective up-regulation of LXR-regulated genes ABCA1, ABCG1, and APOE in macrophages through increased endogenous synthesis of 24(S),25-epoxycholesterol. *Journal of Biological Chemistry*, **2007**, 282, 5207-16	5.4	81
255	Copy number variation in the human genome and its implications for cardiovascular disease. *Circulation*, **2007**, 115, 3130-8	16.7	61
254	Genetic determinants of plasma lipoproteins. *Nature Clinical Practice Cardiovascular Medicine*, **2007**, 4, 600-9		14
253	Stability of lipids on peritoneal dialysis in a patient with familial LCAT deficiency. *Nephrology Dialysis Transplantation*, **2007**, 22, 2084-8	4.3	15
252	Copy-number variations add a new layer of complexity in the human genome. *Cmaj*, **2007**, 176, 441-2	3.5	5
251	Obstructive sleep apnea in 2 women with familial partial lipodystrophy due to a heterozygous LMNA R482Q mutation. *Cmaj*, **2007**, 177, 743-5	3.5	8
250	Treating hypertriglyceridemia. *Cmaj*, **2007**, 177, 604.2-605	3.5	78
249	Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma. *Journal of Clinical Endocrinology and Metabolism*, **2007**, 92, 1606-12	5.6	48
248	Update on the genetics of stroke and cerebrovascular disease 2006. *Stroke*, **2007**, 38, 216-8	6.7	14

247	Resequencing genomic DNA of patients with severe hypertriglyceridemia (MIM 144650). *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2007**, 27, 2450-5	9.4	83
246	Increased enzyme activity and beta-adrenergic mediated vasodilation in subjects expressing a single-nucleotide variant of human adenylyl cyclase 6. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2007**, 27, 2657-63	9.4	9
245	Thematic review series: Adipocyte Biology. Lipodystrophies: windows on adipose biology and metabolism. *Journal of Lipid Research*, **2007**, 48, 1433-44	6.3	101
244	Sanfilippo syndrome type D: natural history and identification of 3 novel mutations in the GNS Gene. *Archives of Neurology*, **2007**, 64, 1629-34		20
243	Hypertriglyceridemia: its etiology, effects and treatment. *Cmaj*, **2007**, 176, 1113-20	3.5	349
242	Common variants APOC3, APOA5, APOE and PON1 are associated with variation in plasma lipoprotein traits in Greenlanders. *International Journal of Circumpolar Health*, **2007**, 66, 390-400	1.7	15
241	Genomic copy number variation and its potential role in lipoprotein and metabolic phenotypes. *Current Opinion in Lipidology*, **2007**, 18, 174-80	4.4	16
240	Copy-number variations and human disease. *American Journal of Human Genetics*, **2007**, 81, 414-5; author reply 415	11	7
239	HIV-associated dyslipidaemia: pathogenesis and treatment. *Lancet Infectious Diseases, The*, **2007**, 7, 787-96	25.5	103
238	The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. *Canadian Journal of Cardiology*, **2007**, 23, 539-50	3.8	76
237	Homozygous missense mutation (G56R) in glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPI-HBP1) in two siblings with fasting chylomicronemia (MIM 144650). *Lipids in Health and Disease*, **2007**, 6, 23	4.4	68
236	Genetic determinants of statin intolerance. *Lipids in Health and Disease*, **2007**, 6, 7	4.4	119
235	Decreased Abdominal Girth and Increased Blood Pressure Associated With a Single Nucleotide Variant of Human Adenylyl Cyclase 6. *FASEB Journal*, **2007**, 21, A795	0.9	
234	Genetic determinants of carotid ultrasound traits. *Current Atherosclerosis Reports*, **2006**, 8, 206-15	6	42
233	A LMNA splicing mutation in two sisters with severe Dunnigan-type familial partial lipodystrophy type 2. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 2689-95	5.6	36
232	Validation of automatically classified magnetic resonance images for carotid plaque compositional analysis. *Stroke*, **2006**, 37, 93-7	6.7	44
231	NPC1L1: evolution from pharmacological target to physiological sterol transporter. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2006**, 26, 2433-8	9.4	63
230	Longitudinal differences in familial combined hyperlipidemia quantitative trait loci. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2006**, 26, e120	9.4	2

229	The heritability of mammographically dense and nondense breast tissue. *Cancer Epidemiology Biomarkers and Prevention*, **2006**, 15, 612-7	4	84
228	Gene therapy with lipoprotein lipase variant S447X. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2006**, 26, e25; author reply e25-8	9.4	4
227	The impact of blunted beta-adrenergic responsiveness on growth regulatory pathways in hypertension. *Molecular Pharmacology*, **2006**, 69, 317-27	4.3	7
226	Genetic susceptibility to heart disease in Canada: lessons from patients with familial hypercholesterolemia. *Genome*, **2006**, 49, 1343-50	2.4	14
225	Sequencing of the reannotated LMNB2 gene reveals novel mutations in patients with acquired partial lipodystrophy. *American Journal of Human Genetics*, **2006**, 79, 383-9	11	156
224	Metabolic syndrome in aboriginal Canadians: prevalence and genetic associations. *Atherosclerosis*, **2006**, 184, 121-9	3.1	70
223	A novel nonsense apolipoprotein A-I mutation (apoA-I(E136X)) causes low HDL cholesterol in French Canadians. *Atherosclerosis*, **2006**, 185, 127-36	3.1	34
222	Genetic determinants of the metabolic syndrome. *Nature Clinical Practice Cardiovascular Medicine*, **2006**, 3, 482-9		110
221	Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. *Cmaj*, **2006**, 174, 1124-9	3.5	78
220	NPC1L1: from drug target to physiological sterol transporter. *Future Lipidology*, **2006**, 1, 247-249		
219	Semi-automated segmentation and quantification of adipose tissue in calf and thigh by MRI: a preliminary study in patients with monogenic metabolic syndrome. *BMC Medical Imaging*, **2006**, 6, 11	2.9	25
218	Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3). *BMC Medical Genetics*, **2006**, 7, 3	2.1	46
217	Relationship of the metabolic syndrome to carotid ultrasound traits. *Cardiovascular Ultrasound*, **2006**, 4, 28	2.4	32
216	A frameshift mutation in peroxisome-proliferator-activated receptor-gamma in familial partial lipodystrophy subtype 3 (FPLD3; MIM 604367). *Clinical Genetics*, **2006**, 70, 360-2	4	24
215	Cockayne syndrome type A: novel mutations in eight typical patients. *Journal of Human Genetics*, **2006**, 51, 701-705	4.3	26
214	Ankyrin G overexpression in Hutchinson-Gilford progeria syndrome fibroblasts identified through biological filtering of expression profiles. *Journal of Human Genetics*, **2006**, 51, 934-942	4.3	13
213	Disparate associations of a functional promoter polymorphism in PCK1 with carotid wall ultrasound traits. *Stroke*, **2005**, 36, 2566-70	6.7	21
212	Differences between carotid wall morphological phenotypes measured by ultrasound in one, two and three dimensions. *Atherosclerosis*, **2005**, 178, 319-25	3.1	80

211	Treatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease. *Lipids in Health and Disease*, **2005**, 4, 26	4.4	48
210	NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe. *Lipids in Health and Disease*, **2005**, 4, 16	4.4	94
209	Compound heterozygosity for two non-synonymous polymorphisms in NPC1L1 in a non-responder to ezetimibe. *Clinical Genetics*, **2005**, 67, 175-7	4	54
208	Quality assessment of microarray experiments. *Clinical Biochemistry*, **2005**, 38, 639-42	3.5	11
207	Identification of a dysfunctional missense single nucleotide variant of human adenylyl cyclase VI. *Clinical Pharmacology and Therapeutics*, **2005**, 77, 271-8	6.1	5
206	Synergism between mutant HNF1A and the metabolic syndrome in Oji-Cree Type 2 diabetes. *Diabetic Medicine*, **2005**, 22, 1510-5	3.5	4
205	LMNA mutation position predicts organ system involvement in laminopathies. *Clinical Genetics*, **2005**, 68, 31-4	4	65
204	Lessons from human mutations in PPARgamma. *International Journal of Obesity*, **2005**, 29 Suppl 1, S31-5	5.5	45
203	Novel mutation in DGUOK in hepatocerebral mitochondrial DNA depletion syndrome associated with cystathioninuria. *American Journal of Medical Genetics, Part A*, **2005**, 135, 289-91	2.5	30
202	Methylenetetrahydrofolate reductase polymorphism 677C>T is associated with peripheral arterial disease in type 2 diabetes. *Cardiovascular Diabetology*, **2005**, 4, 17	8.7	24
201	A comparison of ultrasound measurements to assess carotid atherosclerosis development in subjects with and without type 2 diabetes. *Cardiovascular Ultrasound*, **2005**, 3, 15	2.4	36
200	Genetic and physiological insights into the metabolic syndrome. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2005**, 289, R663-9	3.2	39
199	Multiplex ligation-dependent probe amplification of LDLR enhances molecular diagnosis of familial hypercholesterolemia. *Journal of Lipid Research*, **2005**, 46, 366-72	6.3	60
198	Complex trait locus linkage mapping in atherosclerosis: time to take a step back before moving forward?. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2005**, 25, 1541-4	9.4	15
197	Retinoid X receptor heterodimers in the metabolic syndrome. *New England Journal of Medicine*, **2005**, 353, 2088	59.2	9
196	Cerebral cholesterol granuloma in homozygous familial hypercholesterolemia. *Cmaj*, **2005**, 172, 495-7	3.5	11
195	Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux. *Journal of Biological Chemistry*, **2005**, 280, 22212-21	5.4	101
194	Complications of Type 2 Diabetes Among Aboriginal Canadians: prevalence and associated risk factors. *Diabetes Care*, **2005**, 28, 2054-7	14.6	61

193	Pituitary growth hormone and growth hormone-releasing hormone receptor genes and associations with mammographic measures and serum growth hormone. *Cancer Epidemiology Biomarkers and Prevention*, **2005**, 14, 2648-54	4	22
192	Carotid Ultrasound in One, Two and Three Dimensions. *Vascular Disease Prevention*, **2005**, 2, 87-91		5
191	ABC transporters and sterol absorption. *Current Drug Targets Cardiovascular & Haematological Disorders*, **2005**, 5, 31-7		8
190	Postprandial lipemia in subjects with the threonine 54 variant of the fatty acid-binding protein 2 gene is dependent on the type of fat ingested. *American Journal of Clinical Nutrition*, **2004**, 79, 1110-7	7	51
189	Genetic variation in PPARG encoding peroxisome proliferator-activated receptor gamma associated with carotid atherosclerosis. *Stroke*, **2004**, 35, 2036-40	6.7	83
188	Non-invasive assessment of atherosclerosis risk. *Current Drug Targets Cardiovascular & Haematological Disorders*, **2004**, 4, 125-8		27
187	3D ultrasound imaging of the carotid arteries. *Current Drug Targets Cardiovascular & Haematological Disorders*, **2004**, 4, 161-75		32
186	Promoter polymorphism in PCK1 (phosphoenolpyruvate carboxykinase gene) associated with type 2 diabetes mellitus. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 898-903	5.6	42
185	A single-base mutation in the peroxisome proliferator-activated receptor gamma4 promoter associated with altered in vitro expression and partial lipodystrophy. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 5655-60	5.6	64
184	The metabolic syndrome in Inuit. *Diabetes Care*, **2004**, 27, 1517-8	14.6	6
183	Phenotypic heterogeneity of sitosterolemia. *Journal of Lipid Research*, **2004**, 45, 2361-7	6.3	65
182	Laminopathies and atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2004**, 24, 1591-5	9.4	42
181	Human smooth muscle cell subpopulations differentially accumulate cholesteryl ester when exposed to native and oxidized lipoproteins. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2004**, 24, 1290-6	9.4	40
180	Noninvasive phenotypes of atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2004**, 24, e188; author reply e188-9	9.4	35
179	Noninvasive phenotypes of atherosclerosis: similar windows but different views. *Stroke*, **2004**, 35, 649-53	6.7	125
178	Single nucleotide polymorphism in CTH associated with variation in plasma homocysteine concentration. *Clinical Genetics*, **2004**, 65, 483-6	4	45
177	Hutchinson-Gilford progeria syndrome. *Clinical Genetics*, **2004**, 66, 375-81	4	108
176	Phenomics, lipodystrophy, and the metabolic syndrome. *Trends in Cardiovascular Medicine*, **2004**, 14, 133-7	6.9	31

175	CKN1 (MIM 216400): mutations in Cockayne syndrome type A and a new common polymorphism. *Journal of Human Genetics*, **2004**, 49, 61-63	4.3	21
174	Optimizing RNA extraction yield from whole blood for microarray gene expression analysis. *Clinical Biochemistry*, **2004**, 37, 741-4	3.5	28
173	Venn analysis as part of a bioinformatic approach to prioritize expressed sequence tags from cardiac libraries. *Clinical Biochemistry*, **2004**, 37, 953-60	3.5	3
172	Treatment of partial lipodystrophy: can the zebra teach us about the horse?. *Drug Discovery Today Disease Mechanisms*, **2004**, 1, 195-203		2
171	Thr325Ile polymorphism of the TAFI gene is related to TAFI antigen plasma levels and angiographic restenosis after percutaneous coronary interventions. *Thrombosis Research*, **2004**, 114, 137-41	8.2	12
170	Associations of plasma homocysteine and the methylenetetrahydrofolate reductase C677T polymorphism with carotid intima media thickness among South Asian, Chinese and European Canadians. *Atherosclerosis*, **2004**, 176, 361-70	3.1	49
169	Is regression of coronary atherosclerosis possible by infusing recombinant apolipoprotein A-I?. *Cmaj*, **2004**, 170, 954	3.5	
168	Unbuckling lipodystrophy from insulin resistance and hypertension. *Journal of Clinical Investigation*, **2004**, 114, 163-165	15.9	14
167	Unbuckling lipodystrophy from insulin resistance and hypertension. *Journal of Clinical Investigation*, **2004**, 114, 163-5	15.9	5
166	A glimpse at HDL-based therapy for atherosclerosis. *Clinical Biochemist Reviews*, **2004**, 25, 3-5	7.3	
165	Spectrum of HNF1A and GCK mutations in Canadian families with maturity-onset diabetes of the young (MODY). *Clinical and Investigative Medicine*, **2004**, 27, 135-41	0.9	7
164	Sex, diabetes, and stroke after carotid endarterectomy. *Diabetes Care*, **2003**, 26, 1641	14.6	25
163	Image in cardiovascular medicine. Aortic xanthomatosis with coronary ostial occlusion in a child homozygous for a nonsense mutation in ABCG8. *Circulation*, **2003**, 107, 791	16.7	45
162	Maturity-onset diabetes of the young (MODY) mutation in type 2 diabetes and latent autoimmune diabetes of the adult. *Diabetes Care*, **2003**, 26, 3358-9	14.6	5
161	Genomic organization and evolution of the CX3CR1/CCR8 chemokine receptor locus. *Journal of Biological Chemistry*, **2003**, 278, 11985-94	5.4	21
160	Assembly and secretion of very low density lipoproteins containing apolipoprotein B48 in transfected McA-RH7777 cells. Lack of evidence that palmitoylation of apolipoprotein B48 is required for lipoprotein secretion. *Journal of Biological Chemistry*, **2003**, 278, 14153-61	5.4	15
159	Elevated serum C-reactive protein and free fatty acids among nondiabetic carriers of missense mutations in the gene encoding lamin A/C (LMNA) with partial lipodystrophy. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2003**, 23, 111-6	9.4	54
158	Angiotensinogen M235T genotype predicts progression in chronic renal allograft dysfunction. *Transplantation*, **2003**, 75, 209-16	1.8	8

157	Survival in Academy Award-winning actors and actresses. *Annals of Internal Medicine*, **2003**, 138, 77-8; author reply 77-8	8	1
156	Thrombin-activatable fibrinolysis inhibitor (TAFI): a novel predictor of angiographic coronary restenosis. *Thrombosis and Haemostasis*, **2003**, 90, 1187-91	7	17
155	Lipoprotein lipase (LPL) gene variation and progression of carotid artery plaque. *Stroke*, **2003**, 34, 1176-80	8.7	34
154	LMNA is mutated in Hutchinson-Gilford progeria (MIM 176670) but not in Wiedemann-Rautenstrauch progeroid syndrome (MIM 264090). *Journal of Human Genetics*, **2003**, 48, 271-274	4.3	175
153	DNA polymorphisms of lipase related genes. *Journal of Human Genetics*, **2003**, 48, 443-446	4.3	10
152	DNA polymorphism and mutations in CPN1, including the genomic basis of carboxypeptidase N deficiency. *Journal of Human Genetics*, **2003**, 48, 20-2	4.3	23
151	Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH). *Human Genetics*, **2003**, 112, 404-8	6.3	67
150	Genes, environment and Oji-Cree type 2 diabetes. *Clinical Biochemistry*, **2003**, 36, 163-70	3.5	46
149	APOA1 related amyloidosis: a case report and literature review. *Clinical Biochemistry*, **2003**, 36, 641-5	3.5	52
148	Low incidence of cardiovascular disease among the Inuit--what is the evidence?. *Atherosclerosis*, **2003**, 166, 351-7	3.1	80
147	Identification of a novel lipase gene mutated in lpd mice with hypertriglyceridemia and associated with dyslipidemia in humans. *Human Molecular Genetics*, **2003**, 12, 1131-43	5.6	25
146	Drawing the line in progeria syndromes. *Lancet, The*, **2003**, 362, 416-7	40	19
145	Genomic basis of mucopolysaccharidosis type IIID (MIM 252940) revealed by sequencing of GNS encoding N-acetylglucosamine-6-sulfatase. *Genomics*, **2003**, 81, 1-5	4.3	30
144	Monogenic forms of insulin resistance: apertures that expose the common metabolic syndrome. *Trends in Endocrinology and Metabolism*, **2003**, 14, 371-7	8.8	70
143	Biophysical characteristics of a new mutation on the KCNQ1 potassium channel (L251P) causing long QT syndrome. *Canadian Journal of Physiology and Pharmacology*, **2003**, 81, 129-34	2.4	7
142	Enhanced synthesis of the oxysterol 24(S),25-epoxycholesterol in macrophages by inhibitors of 2,3-oxidosqualene:lanosterol cyclase: a novel mechanism for the attenuation of foam cell formation. *Circulation Research*, **2003**, 93, 717-25	15.7	82
141	Blood pressure among the Inuit (Eskimo) populations in the Arctic. *Scandinavian Journal of Public Health*, **2003**, 31, 92-9	3	29
140	Characterization of a novel mutation causing hepatic lipase deficiency among French Canadians. *Journal of Lipid Research*, **2003**, 44, 1508-14	6.3	24

139	Free fatty acid-mediated impairment of glucose-stimulated insulin secretion in nondiabetic Oji-Cree individuals from the Sandy Lake community of Ontario, Canada: a population at very high risk for developing type 2 diabetes. *Diabetes*, **2003**, 52, 1485-95	0.9	27
138	A novel nontruncating APOB gene mutation, R463W, causes familial hypobetalipoproteinemia. *Journal of Biological Chemistry*, **2003**, 278, 13442-52	5.4	70
137	The fractalkine receptor CX3CR1 is a key mediator of atherogenesis. *Journal of Clinical Investigation* , **2003**, 111, 1118-20	15.9	23
136	A BRCA1 mutation in Native North American families. *Human Mutation*, **2002**, 19, 460	4.7	16
135	GCK and HNF1A mutations in Canadian families with maturity onset diabetes of the young (MODY). *Human Mutation*, **2002**, 20, 478-9	4.7	19
134	Identification of single-nucleotide polymorphisms in the human LPIN1 gene. *Journal of Human Genetics*, **2002**, 47, 370-2	4.3	19
133	Functional promoter polymorphism in SREBP cleavage-activating protein (SCAP). *Journal of Human Genetics*, **2002**, 47, 492-6	4.3	5
132	Polymorphisms in the gene encoding phosphatidylserine-specific phospholipase A1 (PSPLA1). *Journal of Human Genetics*, **2002**, 47, 611-3	4.3	1
131	DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency. *Journal of Human Genetics*, **2002**, 47, 620-2	4.3	75
130	The molecular basis of genetic lipodystrophies. *Clinical Biochemistry*, **2002**, 35, 171-7	3.5	19
129	Successful pregnancy outcome in a patient with severe chylomicronemia due to compound heterozygosity for mutant lipoprotein lipase. *Clinical Biochemistry*, **2002**, 35, 125-30	3.5	26
128	Gene-drug interaction: additive influence of mutant APOA1 and testosterone on plasma HDL-cholesterol. *Clinical Biochemistry*, **2002**, 35, 341-6	3.5	
127	Identification of polymorphisms in the human SHP1 gene. *Journal of Human Genetics*, **2002**, 47, 445-7	4.3	17
126	Association of parity with risk of type 2 diabetes and related metabolic disorders. *Diabetes Care*, **2002**, 25, 690-5	14.6	29
125	HNF-1alpha G319S, a transactivation-deficient mutant, is associated with altered dynamics of diabetes onset in an Oji-Cree community. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 4614-9	11.5	100
124	Functional linkage between the endoplasmic reticulum protein Hsp47 and procollagen expression in human vascular smooth muscle cells. *Journal of Biological Chemistry*, **2002**, 277, 38571-8	5.4	49
123	Cross-sectional and prospective associations between abdominal adiposity and proinsulin concentration. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 77-83	5.6	22
122	A single nucleotide polymorphism in protein tyrosine phosphatase PTP-1B is associated with protection from diabetes or impaired glucose tolerance in Oji-Cree. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 724-7	5.6	63

121	PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. *Diabetes*, **2002**, 51, 3586-90	0.9	217
120	Rapid development of massive tendon xanthomas following highly active antiretroviral therapy. *Annals of Internal Medicine*, **2002**, 137, 624	8	6
119	Environmental modulation of atherosclerosis end points in familial hypercholesterolemia. *Atherosclerosis Supplements*, **2002**, 2, 5-7	1.7	17
118	Beta blockers normalize QT hysteresis in long QT syndrome. *American Heart Journal*, **2002**, 143, 528-34	4.9	42
117	The impact of diabetes on cardiovascular risk factors and outcomes in a native Canadian population. *Diabetes Research and Clinical Practice*, **2002**, 55, 165-73	7.4	51
116	Genes and environment in type 2 diabetes and atherosclerosis in aboriginal Canadians. *Current Atherosclerosis Reports*, **2001**, 3, 216-21	6	15
115	Single nucleotide polymorphisms of the resistin (RSTN) gene. *Journal of Human Genetics*, **2001**, 46, 553-5	4.3	25
114	Low density lipoprotein receptor (LDLR) gene mutations in Canadian subjects with familial hypercholesterolemia, but not of French descent. *Human Mutation*, **2001**, 18, 359	4.7	25
113	Lecithin:cholesterol acyl transferase G30S: association with atherosclerosis, hypoalphalipoproteinemia and reduced in vivo enzyme activity. *Clinical Biochemistry*, **2001**, 34, 381-6	3.5	8
112	Transforming growth factor-beta1 inhibits macrophage cholesteryl ester accumulation induced by native and oxidized VLDL remnants. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2001**, 21, 2011-8	9.4	70
111	Premature atherosclerosis associated with monogenic insulin resistance. *Circulation*, **2001**, 103, 2225-9	16.7	115
110	Common genomic variation in LMNA modulates indexes of obesity in Inuit. *Journal of Clinical Endocrinology and Metabolism*, **2001**, 86, 2747-51	5.6	41
109	Allele frequencies for candidate genes in atherosclerosis and diabetes among Trinidadian neonates. *Human Biology*, **2001**, 73, 525-31	1.2	4
108	Variable association between genetic variation in the CYP7 gene promoter and plasma lipoproteins in three Canadian populations. *Atherosclerosis*, **2001**, 154, 579-87	3.1	28
107	Cholesterol and apolipoprotein B metabolism in Tangier disease. *Atherosclerosis*, **2001**, 159, 231-6	3.1	42
106	Monogenic dyslipidemias: window on determinants of plasma lipoprotein metabolism. *American Journal of Human Genetics*, **2001**, 69, 1161-77	11	62
105	Molecular basis of partial lipodystrophy and prospects for therapy. *Trends in Molecular Medicine*, **2001**, 7, 121-6	11.5	29
104	Serum C-Reactive Protein in Canadian Inuit and Its Association with Genetic Variation on Chromosome 1q21. *Clinical Chemistry*, **2001**, 47, 1707-1709	5.5	9

103	Apolipoprotein E polymorphism and response to electroconvulsive therapy. *Journal of ECT*, **2001**, 17, 11-4	2	13
102	Genes, environment and diabetes in Canadian aboriginal communities. *Advances in Experimental Medicine and Biology*, **2001**, 498, 11-20	3.6	12
101	Association between PON1 L/M55 polymorphism and plasma lipoproteins in two Canadian aboriginal populations. *Clinical Chemistry and Laboratory Medicine*, **2000**, 38, 413-20	5.9	23
100	Microsomal triglyceride transfer protein (MTP) gene mutations in Canadian subjects with abetalipoproteinemia. *Human Mutation*, **2000**, 15, 294-5	4.7	47
99	Insulin resistance in human partial lipodystrophy. *Current Atherosclerosis Reports*, **2000**, 2, 397-404	6	10
98	Human aryl hydrocarbon receptor nuclear translocator gene (ARNT) D/N511 polymorphism. *Journal of Human Genetics*, **2000**, 45, 92-3	4.3	17
97	Human cathepsin S gene (CTSS) promoter -25G/A polymorphism. *Journal of Human Genetics*, **2000**, 45, 94-5	4.3	6
96	Human hepatocyte nuclear factor-1 beta (HNF1B) 1968A/G polymorphism. *Journal of Human Genetics*, **2000**, 45, 98-9	4.3	1
95	Human C-reactive protein (CRP) 1059G/C polymorphism. *Journal of Human Genetics*, **2000**, 45, 100-1	4.3	64
94	Genetic variation in LMNA modulates plasma leptin and indices of obesity in aboriginal Canadians. *Physiological Genomics*, **2000**, 3, 39-44	3.6	54
93	Peroxisome proliferator-activated receptor-gamma2 P12A and type 2 diabetes in Canadian Oji-Cree. *Journal of Clinical Endocrinology and Metabolism*, **2000**, 85, 2014-9	5.6	61
92	Heterogeneity of nuclear lamin A mutations in Dunnigan-type familial partial lipodystrophy. *Journal of Clinical Endocrinology and Metabolism*, **2000**, 85, 3431-5	5.6	50
91	LMNA R482Q mutation in partial lipodystrophy associated with reduced plasma leptin concentration. *Journal of Clinical Endocrinology and Metabolism*, **2000**, 85, 3089-93	5.6	38
90	Variation of candidate genes in triglyceride metabolism. *European Journal of Cardiovascular Prevention and Rehabilitation*, **2000**, 7, 309-15		12
89	Common and rare ABCA1 variants affecting plasma HDL cholesterol. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2000**, 20, 1983-9	9.4	113
88	The private hepatocyte nuclear factor-1alpha G319S variant is associated with plasma lipoprotein variation in Canadian Oji-Cree. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2000**, 20, 217-22	9.4	22
87	Familial partial lipodystrophy: a monogenic form of the insulin resistance syndrome. *Molecular Genetics and Metabolism*, **2000**, 71, 539-44	3.7	54
86	A novel mutation in KVLQT1, L122P, found in a family with autosomal dominant long QT syndrome. *American Heart Journal*, **2000**, 140, 146-9	4.9	7

85	Homocysteine, lipoprotein(a), and restenosis after percutaneous transluminal coronary angioplasty: a prospective study. *American Heart Journal*, **2000**, 140, 272-8	4.9	37
84	G-protein polymorphisms and maternal/neonatal metabolism: still a weight for the answer. *Lancet, The*, **2000**, 355, 1201-2	40	10
83	Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). *Lancet, The*, **2000**, 356, 279-84	40	748
82	NAT2 polymorphism associated with plasma glucose concentration in Canadian Oji-Cree. *Pharmacogenetics and Genomics*, **2000**, 10, 233-8		13
81	Lessons from genetic studies in native Canadian populations. *Nutrition Reviews*, **1999**, 57, S43-9; discussion S49-50	6.4	4
80	Uncovering Rare Mutations: An Unforeseen Complication of Routine Genotyping of APOE. *Clinical Chemistry*, **1999**, 45, 1579-1581	5.5	4
79	Mannose-binding Lectin Gene Variation and Cardiovascular Disease in Canadian Inuit. *Clinical Chemistry*, **1999**, 45, 1283-1285	5.5	16
78	The hepatic nuclear factor-1alpha G319S variant is associated with early-onset type 2 diabetes in Canadian Oji-Cree. *Journal of Clinical Endocrinology and Metabolism*, **1999**, 84, 1077-82	5.6	111
77	Modification of type III VLDL, their remnants, and VLDL from ApoE-knockout mice by p-hydroxyphenylacetaldehyde, a product of myeloperoxidase activity, causes marked cholesteryl ester accumulation in macrophages. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1999**, 19, 1238-49	9.4	27
76	Genetic prediction of coronary heart disease: Lessons from Canada. *Scandinavian Journal of Clinical and Laboratory Investigation*, **1999**, 59, 153-167	2	1
75	Polymorphism in intron 4 of HFE may cause overestimation of C282Y homozygote prevalence in haemochromatosis. *Nature Genetics*, **1999**, 22, 325-6	36.3	151
74	Increased plasma apolipoprotein B-containing lipoproteins associated with increased urinary albumin within the microalbuminuria range in type 2 diabetes. *Clinical Biochemistry*, **1999**, 32, 143-8	3.5	11
73	Association between AGT T235 variant and microalbuminuria in Canadian Oji-Cree with type 2 diabetes mellitus. *Clinical Biochemistry*, **1999**, 32, 201-5	3.5	7
72	Lipoprotein-genotype associations in Trinidadian neonates. *Clinical Biochemistry*, **1999**, 32, 429-37	3.5	10
71	The ADD1 G460W polymorphism is not associated with variation in blood pressure in Canadian Oji-Cree. *Journal of Human Genetics*, **1999**, 44, 225-9	4.3	11
70	Lipoprotein(a) and coronary heart disease risk. *Current Cardiology Reports*, **1999**, 1, 105-11	4.2	28
69	Paraoxonase genes and disease. *Annals of Medicine*, **1999**, 31, 217-24	1.5	78
68	Genetic prediction of atherosclerosis: lessons from studies in native Canadian populations. *Clinica Chimica Acta*, **1999**, 286, 47-61	6.2	19

67	An approach to ascertain probands with a non-traditional risk factor for carotid atherosclerosis. *Atherosclerosis*, **1999**, 144, 429-34	3.1	69
66	Absence of association between genetic variation in the LIPC gene promoter and plasma lipoproteins in three Canadian populations. *Atherosclerosis*, **1999**, 146, 153-60	3.1	53
65	HFE S65C variant is not associated with increased transferrin saturation in voluntary blood donors. *Blood Cells, Molecules, and Diseases*, **1999**, 25, 354-7	2.1	31
64	Plasma homocyst(e)ine concentration, but not MTHFR genotype, is associated with variation in carotid plaque area. *Stroke*, **1999**, 30, 969-73	6.7	109
63	Association of PON2 variation with birth weight in Trinidadian neonates of South Asian ancestry. *Pharmacogenetics and Genomics*, **1999**, 9, 351-6		32
62	Uptake of type IV hypertriglyceridemic VLDL by cultured macrophages is enhanced by interferon-□ *Journal of Lipid Research*, **1999**, 40, 1017-1028	6.3	17
61	A review of intestinal fatty acid binding protein gene variation and the plasma lipoprotein response to dietary components. *Clinical Biochemistry*, **1998**, 31, 609-12	3.5	32
60	Genetics in childhood atherosclerosis. *Progress in Pediatric Cardiology*, **1998**, 9, 213-224	0.4	
59	Hepatic lipase deficiency. *Critical Reviews in Clinical Laboratory Sciences*, **1998**, 35, 547-72	9.4	69
58	Genetic variation in paraoxonase-2 is associated with variation in plasma lipoproteins in Canadian Oji-Cree. *Clinical Genetics*, **1998**, 54, 394-9	4	19
57	Genetic variation in paraoxonase-1 and paraoxonase-2 is associated with variation in plasma lipoproteins in Alberta Hutterites. *Atherosclerosis*, **1998**, 139, 131-6	3.1	59
56	Variation in the AU(AT)-rich element within the 3'-untranslated region of PPP1R3 is associated with variation in plasma glucose in aboriginal Canadians. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 3980-3	5.6	25
55	Elevated LDL triglyceride concentrations in subjects heterozygous for the hepatic lipase S267F variant. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1998**, 18, 1212-6	9.4	9
54	G protein beta3 subunit gene variant and blood pressure variation in Canadian Oji-Cree. *Hypertension*, **1998**, 32, 688-92	8.5	63
53	Hemochromatosis and diabetes mellitus. *Annals of Internal Medicine*, **1998**, 129, 587	8	9
52	Paraoxonase-2 gene (PON2) G148 variant associated with elevated fasting plasma glucose in noninsulin-dependent diabetes mellitus. *Journal of Clinical Endocrinology and Metabolism*, **1997**, 82, 3373-7	5.6	72
51	Candidate genes, small effects, and the prediction of atherosclerosis. *Critical Reviews in Clinical Laboratory Sciences*, **1997**, 34, 343-67	9.4	26
50	V677 mutation of methylenetetrahydrofolate reductases and cardiovascular disease in Canadian Inuit. *Lancet, The*, **1997**, 349, 1221-2	40	41

49	Paraoxonase-2 G148 variant in an aboriginal Canadian girl with non-insulin-dependent diabetes. *Lancet, The*, **1997**, 350, 785	40	14
48	A common mtDNA polymorphism associated with variation in plasma triglyceride concentration. *American Journal of Human Genetics*, **1997**, 60, 1552-5	11	21
47	Apolipoprotein E R112; R251G: a carboxy-terminal variant found in patients with hyperlipidemia and coronary heart disease. *Mutation Research - Mutation Research Genomics*, **1997**, 382, 57-65		1
46	Evidence for gene-diet interaction in the response of blood pressure to dietary fibre. *Nutrition Research*, **1997**, 17, 1229-1238	4	8
45	Uptake of type III hypertriglyceridemic VLDL by macrophages is enhanced by oxidation, especially after remnant formation. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1997**, 17, 1707-15	9.4	42
44	Common genomic variation in the APOC3 promoter associated with variation in plasma lipoproteins. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1997**, 17, 2753-8	9.4	64
43	Small genetic effects in complex diseases: a review of regulatory sequence variants in dyslipoproteinemia and atherosclerosis. *Clinical Biochemistry*, **1997**, 30, 183-8	3.5	12
42	Is it time to measure Lp(a) as part of coronary heart disease risk assessment?. *Clinical Biochemistry*, **1997**, 30, 443-5	3.5	2
41	Common genomic variants associated with variation in plasma lipoproteins in young aboriginal Canadians. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1997**, 17, 1060-6	9.4	51
40	Genetic variation in factor VII associated with variation in plasma lipoprotein(a) concentration. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1997**, 17, 1701-6	9.4	12
39	Angiotensinogen gene variation associated with variation in blood pressure in aboriginal Canadians. *Hypertension*, **1997**, 29, 1073-7	8.5	32
38	The pathogenesis of atherosclerosis. *Clinica Chimica Acta*, **1996**, 246, 21-38	6.2	89
37	Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. *Current Opinion in Lipidology*, **1996**, 7, 69-76	4.4	331
36	Restriction isotyping of the premature termination variant of lipoprotein lipase in Alberta Hutterites. *Clinical Biochemistry*, **1996**, 29, 63-6	3.5	7
35	Genetic diagnosis of familial hypercholesterolemia in affected relatives using pedigree tracing. *Clinical Biochemistry*, **1996**, 29, 371-7	3.5	4
34	Genetic and biochemical factors associated with variation in blood pressure in a genetic isolate. *Hypertension*, **1996**, 27, 308-12	8.5	18
33	Case report: retinopathy and neuropathy associated with complete apolipoprotein A-I deficiency. *American Journal of the Medical Sciences*, **1996**, 312, 30-3	2.2	18
32	Apolipoprotein A-I deficiency. Biochemical and metabolic characteristics. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1995**, 15, 2157-64	9.4	24

31	A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1995**, 15, 89-95	9.4	106
30	Successful outcome in severe pregnancy-associated hyperlipemia: a case report and literature review. *American Journal of the Medical Sciences*, **1995**, 309, 213-8	2.2	37
29	Multiple genetic determinants of variation of plasma lipoproteins in Alberta Hutterites. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1995**, 15, 861-71	9.4	50
28	Apolipoprotein B and E basic amino acid clusters influence low-density lipoprotein association with lipoprotein lipase anchored to the subendothelial matrix. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1995**, 15, 1240-7	9.4	15
27	Genetic variation on chromosome 1 associated with variation in body fat distribution in men. *Circulation*, **1995**, 92, 1089-93	16.7	42
26	Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. *American Journal of Cardiology*, **1994**, 73, 339-45	3	73
25	Effect on blood lipids of very high intakes of fiber in diets low in saturated fat and cholesterol. *New England Journal of Medicine*, **1993**, 329, 21-6	59.2	238
24	A possible escape phenomenon of lipoprotein(a) in sustained plasma exchange. *Transfusion Science*, **1993**, 14, 417-421		
23	Elevated plasma lipoprotein(a) associated with abnormal stress thallium scans in children with familial hypercholesterolemia. *American Journal of Cardiology*, **1993**, 72, 402-6	3	9
22	Genetic variation associated with differences in the response of plasma apolipoprotein B levels to dietary fibre. *Clinical Science*, **1993**, 85, 269-75	6.5	7
21	Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. *American Journal of Cardiology*, **1993**, 72, 171-6	3	409
20	The apolipoprotein E gene and the serum low-density lipoprotein cholesterol response to dietary fiber. *Metabolism: Clinical and Experimental*, **1993**, 42, 585-93	12.7	36
19	Molecular basis and allele specific screening of apolipoprotein CIISt. Michael. *Clinical Biochemistry*, **1992**, 25, 309-12	3.5	3
18	Human hepatic lipase mutations and polymorphisms. *Human Mutation*, **1992**, 1, 320-4	4.7	43
17	Case report: heterogeneity of aldolase B in hereditary fructose intolerance. *American Journal of the Medical Sciences*, **1991**, 302, 364-8	2.2	4
16	Variation within intron 3 of the apolipoprotein CII gene. *Nucleic Acids Research*, **1991**, 19, 3162	20.1	3
15	Compound heterozygosity for mutant hepatic lipase in familial hepatic lipase deficiency. *Biochemical and Biophysical Research Communications*, **1991**, 179, 78-84	3.4	30
14	Linkage disequilibrium between DNA markers at the low-density lipoprotein receptor gene. *Genetic Epidemiology*, **1990**, 7, 69-81	2.6	26

13	Lipoprotein(a) and Plasminogen: Linkage Analysis **1990**, 129-139		1
12	Allele frequencies of apolipoprotein A-I and A-II gene locus DNA polymorphisms in Boston-based whites. *Human Heredity*, **1989**, 39, 174-8	1.1	6
11	Clinical application of deoxyribonucleic acid markers in a Utah family with hypercholesterolemia. *American Journal of Cardiology*, **1989**, 63, 109-12	3	16
10	Genetic linkage between lipoprotein(a) phenotype and a DNA polymorphism in the plasminogen gene. *Genomics*, **1988**, 3, 230-6	4.3	94
9	Apolipoprotein genetic variation in the assessment of atherosclerosis susceptibility. *Genetic Epidemiology*, **1987**, 4, 163-84	2.6	49
8	Apolipoprotein B-gene DNA polymorphisms associated with myocardial infarction. *New England Journal of Medicine*, **1986**, 315, 1509-15	59.2	262
7	Pituitary apoplexy associated with a triple bolus test. Case report. *Journal of Neurosurgery*, **1984**, 61, 586-90	3.2	51
6	Cross-Sectional and Prospective Associations between Abdominal Adiposity and Proinsulin Concentration		7
5	The Ontario Neurodegenerative Disease Research Initiative		6
4	Exautomate: A user-friendly tool for region-based rare variant association analysis (RVAA)		1
3	Molecular Genetics of Hypertriglyceridaemia1-8		
2	The Clinical Genome Resource (ClinGen) Familial Hypercholesterolemia Variant Curation Expert Panel consensus guidelines for LDLR variant classification		1
1	Overview of Acquired and Genetic Lipodystrophies385-402		1